{"entity":{"id":"2019","kind":"year","name":"2019 in oncology","aka":["2019"],"tldr":"Everything OnCo dates to 2019: 661 entries, 190 papers, 172 papers listed on people's pages, 113 landmarks and 79 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"661 dated entries in OnCo fall in 2019: 190 papers, 172 papers listed on people's pages, 113 landmarks, 79 trials reported, 55 approvals, 18 regulatory events, 10 companies founded, 6 journals founded, 5 financing rounds, 5 laws and regulations, 5 guideline changes and 3 technologies.\n\nOf those, 15 to the day, 8 to the month and 638 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2018","2020"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2019,"events":[{"group":"approval","date":"2019","precision":"year","title":"Acalabrutinib approved in US","note":"CLL/SLL, first-line and relapsed (ELEVATE-TN, ASCEND)","from":"acalabrutinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Alpelisib approved in US","note":"PIK3CA-mutant HR+/HER2- advanced breast cancer with fulvestrant after endocrine therapy","from":"alpelisib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Anlotinib approved in China","note":"Advanced soft tissue sarcoma after chemotherapy; small cell lung cancer after at least two lines","from":"anlotinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Apalutamide approved in US","note":"mHSPC (TITAN)","from":"apalutamide","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Atezolizumab approved in England (NICE)","note":"Metastatic non-squamous non-small-cell lung cancer, with bevacizumab, carboplatin and paclitaxel.","from":"atezolizumab","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Atezolizumab approved in EU","note":"Unresectable locally advanced or metastatic TNBC with PD-L1 expression of 1 percent or more (SP142 immune cells), with nab-paclitaxel, no prior chemotherapy for metastatic disease...","from":"atezolizumab","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Axitinib approved in US","note":"First-line advanced RCC with pembrolizumab or avelumab","from":"axitinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"BRACAnalysis CDx approved in US","note":"Olaparib maintenance in germline BRCA-mutated metastatic pancreatic cancer","from":"bracanalysis-cdx","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Brigatinib approved in England (NICE)","note":"ALK-positive advanced non-small-cell lung cancer after crizotinib. TA571, published 20 March 2019, subject to the commercial arrangement.","from":"brigatinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Cabozantinib approved in US","note":"HCC previously treated with sorafenib","from":"cabozantinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Camrelizumab approved in China","note":"Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal","from":"camrelizumab","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Dacomitinib approved in England (NICE)","note":"Untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer. TA595, published 14 August 2019, subject to the commercial arrangement (ARCHER 1050).","from":"dacomitinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Dacomitinib approved in EU","note":"Same","from":"dacomitinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Daratumumab approved in US","note":"Newly diagnosed, transplant-ineligible with Rd (MAIA) and VMP","from":"daratumumab","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Darolutamide approved in US","note":"Non-metastatic CRPC","from":"darolutamide","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Dexamethasone approved in US","note":"Multiple myeloma in combination with other antimyeloma products (Hemady)","from":"dexamethasone","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Enfortumab vedotin approved in US","note":"Advanced urothelial cancer after platinum and PD-1/PD-L1 (accelerated)","from":"enfortumab-vedotin","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Entrectinib approved in JP","note":"NTRK fusion solid tumours","from":"entrectinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Entrectinib approved in US","note":"ROS1-positive metastatic NSCLC; NTRK fusion solid tumours (≥12 years, extended to ≥1 month 2023)","from":"entrectinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Enzalutamide approved in US","note":"mHSPC (ARCHES)","from":"enzalutamide","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Erdafitinib approved in US","note":"FGFR3/2-altered advanced urothelial cancer after platinum (accelerated)","from":"erdafitinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Fedratinib approved in US","note":"Intermediate-2/high-risk primary or secondary myelofibrosis","from":"fedratinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Flumatinib approved in CN","note":"Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia, chronic phase","from":"flumatinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"FoundationOne CDx / Liquid CDx approved in EU","note":"CE-IVD","from":"foundationone-cdx","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Ivosidenib approved in US","note":"Newly diagnosed IDH1-mutated AML unfit for intensive chemotherapy","from":"ivosidenib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Larotrectinib approved in EU","note":"Same","from":"larotrectinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Lunit INSIGHT MMG approved in EU","note":"CE mark","from":"lunit-insight-mmg","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Luspatercept approved in US","note":"Beta-thalassaemia transfusion-dependent anaemia","from":"luspatercept","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Mia (Mammography Intelligent Assessment) approved in EU","note":"CE mark, mammography decision support","from":"kheiron-mia","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"myChoice CDx approved in US","note":"Companion diagnostic for niraparib in HRD-positive advanced ovarian cancer","from":"mychoice-cdx","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"NBTXR3 (hafnium oxide nanoparticles) approved in EU","note":"CE mark: locally advanced soft-tissue sarcoma of the limb or trunk wall, with preoperative radiotherapy","from":"nbtxr3","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Obinutuzumab approved in US","note":"Previously untreated CLL with venetoclax, fixed duration (CLL14); with acalabrutinib (ELEVATE-TN)","from":"obinutuzumab","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Olaparib approved in EU","note":"Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer after an anthracycline and a taxane (OlympiAD).","from":"olaparib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Olaparib approved in US","note":"Maintenance treatment of deleterious or suspected deleterious germline BRCA-mutated metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of fi...","from":"olaparib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Oncomine Dx Target Test approved in Japan","note":"Multi-gene companion diagnostic system for NSCLC","from":"oncomine-dx-target-test","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Paige Prostate Detect approved in EU","note":"CE mark","from":"paige-prostate","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"PD-L1 IHC 22C3 pharmDx approved in US","note":"Head and neck squamous cell carcinoma (CPS ≥1) and oesophageal squamous cell carcinoma (CPS ≥10)","from":"dako-pd-l1-22c3-pharmdx","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Pexidartinib approved in US","note":"Symptomatic tenosynovial giant cell tumour not amenable to surgery","from":"pexidartinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Polatuzumab vedotin approved in US","note":"Relapsed/refractory DLBCL with bendamustine-rituximab after ≥2 lines (accelerated)","from":"polatuzumab-vedotin","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"ProFound AI (iCAD) approved in EU","note":"CE mark","from":"icad-profound-ai","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Quizartinib approved in Japan","note":"Relapsed/refractory FLT3-ITD AML","from":"quizartinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Ramucirumab approved in US","note":"HCC with AFP ≥400 ng/mL after sorafenib","from":"ramucirumab","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Ropeginterferon alfa-2b approved in EU","note":"Polycythaemia vera without symptomatic splenomegaly","from":"ropeginterferon-alfa-2b","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Ruxolitinib approved in US","note":"Steroid-refractory acute GVHD","from":"ruxolitinib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Selinexor approved in US","note":"Relapsed/refractory multiple myeloma (≥4 lines) with dexamethasone","from":"selinexor","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Talazoparib approved in EU","note":"Germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer (EMBRACA); marketing authorisation issued 20 June 2019.","from":"talazoparib","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF) approved in US","note":"therascreen PIK3CA (tissue and plasma): alpelisib in breast cancer; therascreen FGFR: erdafitinib in urothelial cancer","from":"therascreen-cdx","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Tislelizumab approved in China","note":"Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal","from":"tislelizumab","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Trastuzumab deruxtecan approved in US","note":"HER2+ metastatic breast cancer, ≥2 prior anti-HER2 regimens","from":"trastuzumab-deruxtecan","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Trastuzumab emtansine approved in US","note":"Adjuvant HER2+ breast cancer with residual disease after neoadjuvant therapy","from":"trastuzumab-emtansine","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Treosulfan approved in EU","note":"Conditioning before allogeneic HSCT (with fludarabine) in adults and children","from":"treosulfan","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Trifluridine/tipiracil approved in US","note":"Refractory metastatic gastric/GEJ cancer (TAGS)","from":"trifluridine-tipiracil","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Tucidinostat (chidamide) approved in China","note":"HR-positive, HER2-negative advanced breast cancer with exemestane after endocrine therapy (ACE)","from":"tucidinostat","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"VENTANA PD-L1 (SP142) Assay approved in US","note":"Companion diagnostic for atezolizumab in PD-L1 IC ≥1% triple-negative breast cancer","from":"ventana-pd-l1-sp142","refs":[]},{"group":"approval","date":"2019","precision":"year","title":"Zanubrutinib approved in US","note":"Relapsed MCL (accelerated)","from":"zanubrutinib","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Anbogen Therapeutics founded","note":"Taipei","from":"anbogen-therapeutics","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Aqemia founded","note":"Paris","from":"aqemia","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Careology founded","note":"London","from":"careology","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Grit Bio founded","note":"Beijing","from":"grit-bio","refs":[]},{"group":"company","date":"2019","precision":"year","title":"HiberCell founded","note":"New York, NY","from":"hibercell","refs":[]},{"group":"company","date":"2019","precision":"year","title":"LaNova Medicines founded","note":"Shanghai","from":"lanova-medicines","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Remix Therapeutics founded","note":"Watertown, Massachusetts","from":"remix-therapeutics","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Shanghai Juncell Therapeutics founded","note":"Shanghai","from":"shanghai-juncell-therapeutics","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Suzhou Forlong Biotechnology founded","note":"Suzhou","from":"suzhou-forlong-biotechnology","refs":[]},{"group":"company","date":"2019","precision":"year","title":"Triana Biomedicines founded","note":"Lexington, MA","from":"triana-biomedicines","refs":[]},{"group":"funding","date":"2019","precision":"year","title":"Careology: Seed","note":"GBP 1.12 million from UK health and technology angel investors (not named)","from":"careology","refs":[]},{"group":"funding","date":"2019","precision":"year","title":"Geneos Therapeutics: Series A","note":"$11m","from":"geneos-therapeutics","refs":[]},{"group":"funding","date":"2019","precision":"year","title":"IDEAYA Biosciences: IPO","note":"$58m. 5.75 million shares at 10 US dollars, including full exercise of the underwriters' option","from":"ideaya-biosciences","refs":[]},{"group":"funding","date":"2019","precision":"year","title":"Kumquat Biosciences: Form D offering","note":"$56m. Total sold per amended Form D filed August 2019","from":"kumquat-biosciences","refs":[]},{"group":"funding","date":"2019","precision":"year","title":"Tmunity Therapeutics: Form D offering","note":"$75m. Equity offering, first sale 22 October 2019","from":"tmunity-therapeutics","refs":[]},{"group":"history","date":"2019","precision":"year","title":"Ablative MR-guided radiotherapy for locally advanced disease enters trials","note":"Locally advanced unresectable pancreatic ductal adenocarcinoma","from":"locally-advanced-pdac","refs":["mr-linac","sbrt"]},{"group":"history","date":"2019","precision":"year","title":"ACNS0121 confirms post-operative conformal radiotherapy","note":"Ependymoma. COG phase 2 (JCO 2019) reports outcomes by extent of resection and molecular group.","from":"ependymoma","refs":[]},{"group":"history","date":"2019","precision":"year","title":"Alpelisib approved for PIK3CA-mutant disease (SOLAR-1)","note":"HR-positive metastatic breast cancer after CDK4/6 inhibitors","from":"hr-positive-metastatic-post-cdk46","refs":["solar-1","alpelisib"]},{"group":"history","date":"2019","precision":"year","title":"Alpelisib: first PI3K inhibitor in breast cancer","note":"HR-positive / HER2-negative breast cancer","from":"breast-hr-positive","refs":["alpelisib","solar-1"]},{"group":"history","date":"2019","precision":"year","title":"ANBL0531: further response-based reduction, two cycles for the most favourable children","note":"Intermediate-risk neuroblastoma","from":"neuroblastoma-intermediate-risk","refs":["inrg-staging"]},{"group":"history","date":"2019","precision":"year","title":"ANBL0532: tandem transplant beats single transplant","note":"High-risk neuroblastoma","from":"neuroblastoma-high-risk","refs":["anbl0532","tandem-transplant"]},{"group":"history","date":"2019","precision":"year","title":"ANBL0532: tandem transplant improves EFS (JAMA)","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["anbl0532","tandem-transplant"]},{"group":"history","date":"2019","precision":"year","title":"ANNOUNCE fails; olaratumab withdrawn","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["announce"]},{"group":"history","date":"2019","precision":"year","title":"ANNOUNCE: olaratumab fails and is withdrawn","note":"Soft tissue sarcoma of the extremity (localised and advanced)","from":"extremity-soft-tissue-sarcoma","refs":["announce"]},{"group":"history","date":"2019","precision":"year","title":"ARAMIS: darolutamide approved for nmCRPC","note":"Non-metastatic castration-resistant prostate cancer","from":"prostate-nmcrpc","refs":["darolutamide"]},{"group":"history","date":"2019","precision":"year","title":"AREN0532: surgery alone confirmed for very-low-risk stage I","note":"Wilms tumour (nephroblastoma)","from":"wilms-tumor","refs":["active-surveillance"]},{"group":"history","date":"2019","precision":"year","title":"ARST0531: irinotecan does not improve outcome but spares cyclophosphamide","note":"Rhabdomyosarcoma","from":"rhabdomyosarcoma","refs":["irinotecan"]},{"group":"history","date":"2019","precision":"year","title":"Autologous transplant in HIV lymphoma (BMT CTN 0803 / AMC 071)","note":"HIV-associated (AIDS-related) lymphomas. Outcomes comparable to HIV-negative controls.","from":"hiv-associated-lymphoma","refs":["autologous-stem-cell-transplant"]},{"group":"history","date":"2019","precision":"year","title":"BEACON CRC gives BRAF V600E disease a targeted option","note":"Colorectal cancer. 665 patients; encorafenib with cetuximab and binimetinib 9.0 versus 5.4 months, the doublet 8.4 months.","from":"colorectal","refs":["paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019","beacon-crc"]},{"group":"history","date":"2019","precision":"year","title":"BEACON CRC: encorafenib plus cetuximab improves survival after prior therapy","note":"BRAF V600E-mutant colorectal cancer","from":"braf-v600e-colorectal","refs":["beacon-crc","encorafenib","cetuximab"]},{"group":"history","date":"2019","precision":"year","title":"BILCAP: adjuvant capecitabine","note":"Gallbladder cancer. Six months of capecitabine after resection of biliary tract cancer becomes the adjuvant standard.","from":"gallbladder","refs":["bilcap"]},{"group":"history","date":"2019","precision":"year","title":"BILCAP: adjuvant capecitabine after resection","note":"Intrahepatic cholangiocarcinoma","from":"intrahepatic-cholangiocarcinoma","refs":["bilcap","capecitabine"]},{"group":"history","date":"2019","precision":"year","title":"BILCAP: adjuvant capecitabine after resection","note":"Extrahepatic cholangiocarcinoma (perihilar and distal)","from":"extrahepatic-cholangiocarcinoma","refs":["bilcap","capecitabine"]},{"group":"history","date":"2019","precision":"year","title":"CALGB 10403: paediatric regimen in adults 17 to 39 published; FDA guidance on including adolescents in adult cancer trials","note":"Adolescent and young adult cancers (ages 15 to 39)","from":"aya-cancers","refs":["asparaginase"]},{"group":"history","date":"2019","precision":"year","title":"CASPIAN confirms chemo-immunotherapy with durvalumab","note":"Small-cell lung cancer","from":"sclc","refs":["caspian","durvalumab"]},{"group":"history","date":"2019","precision":"year","title":"CASPIAN: durvalumab plus chemotherapy","note":"Extensive-stage small-cell lung cancer","from":"extensive-stage-sclc","refs":["caspian","durvalumab","luis-paz-ares"]},{"group":"history","date":"2019","precision":"year","title":"CASPS: cediranib improves progression-free survival against placebo","note":"Alveolar soft part sarcoma","from":"alveolar-soft-part-sarcoma","refs":[]},{"group":"history","date":"2019","precision":"year","title":"CASSIOPEIA: daratumumab quadruplet raises deep responses","note":"Newly diagnosed multiple myeloma, transplant-eligible","from":"myeloma-transplant-eligible","refs":["daratumumab"]},{"group":"history","date":"2019","precision":"year","title":"CheckMate 436: nivolumab plus brentuximab vedotin, 73 percent response rate","note":"Primary mediastinal (thymic) large B-cell lymphoma","from":"primary-mediastinal-b-cell-lymphoma","refs":["nivolumab","brentuximab-vedotin"]},{"group":"history","date":"2019","precision":"year","title":"CLL14: one year of venetoclax-obinutuzumab approved; ELEVATE-TN reports acalabrutinib","note":"Chronic lymphocytic leukaemia, first treatment","from":"cll-treatment-naive","refs":["cll14","venetoclax","elevate-tn","acalabrutinib"]},{"group":"history","date":"2019","precision":"year","title":"Cobimetinib effective regardless of genotype","note":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. Diamond and colleagues, Nature Medicine 2019.","from":"histiocytoses","refs":["cobimetinib"]},{"group":"history","date":"2019","precision":"year","title":"Cobimetinib phase 2 shows responses in most patients regardless of mutation","note":"Erdheim-Chester disease","from":"erdheim-chester-disease","refs":["cobimetinib"]},{"group":"history","date":"2019","precision":"year","title":"COMPASS, targeted profiling at scale and ctDNA as a clinical test","note":"Pancreatic ductal adenocarcinoma. Classical tumours respond to chemotherapy three times as often as basal-like; 3,594 profiled tumours give KRAS 88% and MSI or TMB-high 0.5%; a CLI...","from":"pancreatic","refs":["paper-okane-gata6-basal-like-compass-ccr-2020","paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019","ctdna-mrd-positive"]},{"group":"history","date":"2019","precision":"year","title":"England replaces the guaiac test with the faecal immunochemical test","note":"Colorectal cancer. From June 2019 every screening invitation in England carries a faecal immunochemical test kit, read at a threshold of 120 micrograms of haemoglobin per gram of f...","from":"colorectal","refs":["fit-test","bowel-cancer-screening-uk"]},{"group":"history","date":"2019","precision":"year","title":"England starts the Targeted Lung Health Check programme","note":"Lung cancer (all types). Mobile CT scanners parked in supermarket car parks in the areas with the highest lung cancer rates, inviting ever-smokers aged 55 to 74 through their GP re...","from":"lung-cancer","refs":["nhs-targeted-lung-health-check","targeted-lung-health-check"]},{"group":"history","date":"2019","precision":"year","title":"ENLIVEN phase 3 and FDA approval of pexidartinib","note":"Tenosynovial giant cell tumour (TGCT). First systemic therapy approved for TGCT (August 2019), with a boxed hepatotoxicity warning.","from":"tenosynovial-giant-cell-tumour","refs":["pexidartinib"]},{"group":"history","date":"2019","precision":"year","title":"Entrectinib approved for NTRK fusion tumours and ROS1 lung cancer","note":"NTRK fusion-positive non-small-cell lung cancer","from":"ntrk-fusion-nsclc","refs":["entrectinib","nct02568267"]},{"group":"history","date":"2019","precision":"year","title":"Entrectinib approved for ROS1 lung cancer and NTRK fusion tumours","note":"ROS1-positive non-small-cell lung cancer","from":"ros1-positive-nsclc","refs":["entrectinib","nct02568267","alexander-drilon"]},{"group":"history","date":"2019","precision":"year","title":"EpSSG RMS 2005: maintenance vinorelbine-cyclophosphamide improves survival (Lancet Oncol)","note":"Rhabdomyosarcoma","from":"rhabdomyosarcoma","refs":["vinorelbine","cyclophosphamide"]},{"group":"history","date":"2019","precision":"year","title":"Erdafitinib (first targeted therapy) and enfortumab vedotin (first ADC) approved","note":"Bladder & urothelial cancer","from":"urothelial","refs":["erdafitinib","enfortumab-vedotin"]},{"group":"history","date":"2019","precision":"year","title":"Erdafitinib: first targeted drug for FGFR3-altered urothelial cancer","note":"Muscle-invasive and advanced bladder cancer","from":"muscle-invasive-bladder-cancer","refs":["erdafitinib"]},{"group":"history","date":"2019","precision":"year","title":"Fedratinib approved","note":"Myeloproliferative neoplasms (PV, ET, myelofibrosis). JAKARTA; the second JAK inhibitor after an eight-year gap.","from":"myeloproliferative-neoplasms","refs":["fedratinib"]},{"group":"history","date":"2019","precision":"year","title":"Fedratinib approved after JAKARTA","note":"Primary myelofibrosis","from":"primary-myelofibrosis","refs":["fedratinib"]},{"group":"history","date":"2019","precision":"year","title":"Fixed-duration therapy: CLL14; acalabrutinib approved","note":"Chronic lymphocytic leukaemia. Venetoclax-obinutuzumab for 12 months; ELEVATE-TN and ASCEND establish acalabrutinib.","from":"cll","refs":["cll14","acalabrutinib","elevate-tn"]},{"group":"history","date":"2019","precision":"year","title":"FLOT4: docetaxel quadruplet becomes perioperative standard; trifluridine/tipiracil third line (TAGS)","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["flot","trifluridine-tipiracil"]},{"group":"history","date":"2019","precision":"year","title":"FLOT4: perioperative FLOT beats ECF","note":"Oesophageal and junctional adenocarcinoma","from":"oesophageal-adenocarcinoma","refs":["flot"]},{"group":"history","date":"2019","precision":"year","title":"Four kinds of small-cell lung cancer, and plasma as a first test","note":"Non-small-cell lung cancer. Transcription factor expression splits small-cell disease into four subtypes; in parallel, cell-free DNA is shown to be non-inferior to tissue genotypin...","from":"nsclc","refs":["paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019"]},{"group":"history","date":"2019","precision":"year","title":"GEFCAPI 04: classifier-directed therapy does not beat empirical chemotherapy","note":"Cancer of unknown primary, favourable subsets","from":"cup-favourable-subsets","refs":[]},{"group":"history","date":"2019","precision":"year","title":"GEFCAPI 04: site-specific therapy by classifier no better than empirical chemotherapy","note":"Cancer of unknown primary, unfavourable (adenocarcinoma and poorly differentiated carcinoma)","from":"cup-unfavourable","refs":[]},{"group":"history","date":"2019","precision":"year","title":"GEFCAPI 04: site-specific therapy by molecular classifier no better than empiric chemotherapy","note":"Cancer of unknown primary (CUP)","from":"cancer-of-unknown-primary","refs":[]},{"group":"history","date":"2019","precision":"year","title":"Genomic studies show KRAS and GNAS mutations and few APC mutations, distinguishing appendiceal from colorectal cancer","note":"Appendiceal adenocarcinoma (mucinous and non-mucinous, including signet ring cell)","from":"appendiceal-adenocarcinoma","refs":[]},{"group":"history","date":"2019","precision":"year","title":"HYPO-RT-PC: seven fractions match 39","note":"Localised prostate cancer, intermediate risk","from":"prostate-intermediate-risk","refs":["hypo-rt-pc"]},{"group":"history","date":"2019","precision":"year","title":"Induction gemcitabine-cisplatin improves survival (Zhang, NEJM)","note":"Nasopharyngeal carcinoma","from":"nasopharyngeal","refs":["gemcitabine-cisplatin"]},{"group":"history","date":"2019","precision":"year","title":"Induction gemcitabine-cisplatin improves survival in locoregionally advanced disease","note":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","from":"locoregionally-advanced-nasopharyngeal-carcinoma","refs":["gemcitabine-cisplatin"]},{"group":"history","date":"2019","precision":"year","title":"Interfant-06: AML-type intensification adds nothing; six-year event-free survival 46 percent","note":"Infant acute lymphoblastic leukaemia (KMT2A-rearranged, under one year)","from":"all-infant","refs":["interfant-06"]},{"group":"history","date":"2019","precision":"year","title":"KEYNOTE-042: monotherapy label widened to PD-L1 of 1 percent or more, benefit concentrated at 50 percent or more","note":"PD-L1-high non-small-cell lung cancer without a driver mutation","from":"pdl1-high-nsclc","refs":["keynote-042","pembrolizumab","tony-mok"]},{"group":"history","date":"2019","precision":"year","title":"KEYNOTE-048: IO first line","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":[]},{"group":"history","date":"2019","precision":"year","title":"KEYNOTE-048: pembrolizumab first line","note":"Recurrent or metastatic head and neck squamous cell carcinoma","from":"recurrent-metastatic-hnscc","refs":["keynote-048"]},{"group":"history","date":"2019","precision":"year","title":"KEYNOTE-048: pembrolizumab first line in recurrent disease","note":"HPV-negative head and neck squamous cell carcinoma (including HPV-negative oropharyngeal cancer)","from":"hpv-negative-head-and-neck-cancer","refs":["keynote-048"]},{"group":"history","date":"2019","precision":"year","title":"KEYNOTE-048: pembrolizumab first line in recurrent disease","note":"Hypopharyngeal cancer","from":"hypopharyngeal-cancer","refs":["keynote-048"]},{"group":"history","date":"2019","precision":"year","title":"KEYNOTE-048: pembrolizumab first line in recurrent disease","note":"Oral tongue and floor of mouth cancer","from":"oral-tongue-cancer","refs":["keynote-048"]},{"group":"history","date":"2019","precision":"year","title":"KEYNOTE-048: pembrolizumab first line; RTOG 1016 and De-ESCALaTE show cetuximab cannot replace cisplatin","note":"Head and neck squamous cell carcinoma","from":"head-and-neck","refs":["keynote-048","hpv-deescalation-caution"]},{"group":"history","date":"2019","precision":"year","title":"Lenvatinib + pembrolizumab accelerated approval (KEYNOTE-146)","note":"Endometrial cancer","from":"endometrial","refs":["lenvatinib"]},{"group":"history","date":"2019","precision":"year","title":"Lenvatinib phase 2: median progression-free survival 17.5 months","note":"Adenoid cystic carcinoma","from":"adenoid-cystic-carcinoma","refs":["lenvatinib"]},{"group":"history","date":"2019","precision":"year","title":"LUME-Meso fails; nintedanib abandoned in mesothelioma","note":"Mesothelioma","from":"mesothelioma","refs":["lume-meso","nintedanib"]},{"group":"history","date":"2019","precision":"year","title":"MAIA: Dara-Rd improves survival in transplant-ineligible disease","note":"Multiple myeloma","from":"multiple-myeloma","refs":["daratumumab"]},{"group":"history","date":"2019","precision":"year","title":"MAIA: daratumumab-Rd approved for transplant-ineligible myeloma","note":"Newly diagnosed multiple myeloma, transplant-ineligible","from":"myeloma-transplant-ineligible","refs":["daratumumab"]},{"group":"history","date":"2019","precision":"year","title":"MD Anderson series: induction response guides local therapy and improves survival","note":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","from":"sinonasal-undifferentiated-carcinoma","refs":["platinum-etoposide"]},{"group":"history","date":"2019","precision":"year","title":"mEOC/GOG 241 randomised trial closes early for poor accrual","note":"Mucinous ovarian cancer","from":"mucinous-ovarian-cancer","refs":[]},{"group":"history","date":"2019","precision":"year","title":"Meta-analysis of MAGIC, CLASSIC, ARTIST and ITACA-S: no chemotherapy benefit in MSI-high tumours","note":"Microsatellite-unstable (MSI-high) gastric cancer","from":"gastric-msi-high","refs":[]},{"group":"history","date":"2019","precision":"year","title":"miR-371a-3p validated as a serum marker (Dieckmann, JCO)","note":"Testicular germ cell tumours","from":"testicular","refs":[]},{"group":"history","date":"2019","precision":"year","title":"MyPathway: trastuzumab plus pertuzumab active in HER2-amplified colorectal cancer","note":"HER2-amplified colorectal cancer","from":"her2-amplified-colorectal","refs":["mypathway","pertuzumab","trastuzumab"]},{"group":"history","date":"2019","precision":"year","title":"NCCN publishes dedicated SBA guideline","note":"Small intestine cancer (small bowel adenocarcinoma)","from":"small-bowel","refs":[]},{"group":"history","date":"2019","precision":"year","title":"NCCN publishes its first guideline for small bowel adenocarcinoma","note":"Localised small bowel adenocarcinoma (stage I to III, resected)","from":"localised-small-bowel-adenocarcinoma","refs":[]},{"group":"history","date":"2019","precision":"year","title":"PARP maintenance extends beyond BRCA","note":"Ovarian cancer. PRIMA (niraparib, all comers) and PAOLA-1 (olaparib + bevacizumab, HRD-positive).","from":"ovarian","refs":["prima","paola-1"]},{"group":"history","date":"2019","precision":"year","title":"PD-1 blockade second line: pembrolizumab (KEYNOTE-181) and nivolumab (ATTRACTION-3)","note":"Oesophageal cancer","from":"esophageal","refs":["pembrolizumab","nivolumab"]},{"group":"history","date":"2019","precision":"year","title":"Pembrolizumab first line in recurrent disease (KEYNOTE-048)","note":"Oropharyngeal cancer (tonsil and base of tongue)","from":"oropharyngeal-cancer","refs":["keynote-048"]},{"group":"history","date":"2019","precision":"year","title":"Pembrolizumab phase 2 in ACC (Raj, JCO)","note":"Adrenocortical carcinoma","from":"adrenocortical","refs":["pembrolizumab"]},{"group":"history","date":"2019","precision":"year","title":"Pembrolizumab plus axitinib first line (KEYNOTE-426)","note":"Clear cell renal cell carcinoma","from":"clear-cell-rcc","refs":["keynote-426"]},{"group":"history","date":"2019","precision":"year","title":"Pembrolizumab-axitinib and avelumab-axitinib: IO-TKI era begins","note":"Renal cell carcinoma","from":"rcc","refs":["keynote-426","axitinib","avelumab"]},{"group":"history","date":"2019","precision":"year","title":"PERSEPHONE: six months of trastuzumab nearly as good as twelve","note":"Early HER2-positive breast cancer","from":"her2-positive-early-breast-cancer","refs":["persephone"]},{"group":"history","date":"2019","precision":"year","title":"Phase 1b: trastuzumab deruxtecan responses in HER2-low tumours","note":"HER2-low and HER2-ultralow metastatic breast cancer","from":"her2-low-metastatic-breast-cancer","refs":["trastuzumab-deruxtecan"]},{"group":"history","date":"2019","precision":"year","title":"PLATO trials open to personalise radiotherapy dose by stage","note":"Localised anal squamous cell carcinoma (stage I to III)","from":"localised-anal-cancer","refs":["imrt-igrt"]},{"group":"history","date":"2019","precision":"year","title":"Polatuzumab vedotin approved with BR for relapsed disease","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["polatuzumab-vedotin"]},{"group":"history","date":"2019","precision":"year","title":"POLO: olaparib maintenance delays progression in germline BRCA carriers","note":"Metastatic pancreatic ductal adenocarcinoma","from":"metastatic-pdac","refs":["polo","olaparib","talia-golan"]},{"group":"history","date":"2019","precision":"year","title":"POLO: olaparib maintenance delays progression in germline BRCA carriers; FDA approval in December","note":"BRCA or PALB2-mutant pancreatic ductal adenocarcinoma","from":"brca-palb2-pdac","refs":["polo","olaparib","talia-golan","astrazeneca"]},{"group":"history","date":"2019","precision":"year","title":"POLO: olaparib maintenance in gBRCA","note":"Pancreatic ductal adenocarcinoma. First biomarker-directed approval.","from":"pancreatic","refs":["polo","olaparib"]},{"group":"history","date":"2019","precision":"year","title":"Population whole genomes and TILs","note":"Triple-negative breast cancer (TNBC). SCAN-B whole-genome sequencing puts HRDetect-high at 59% of TNBC (Nat Med); Loi's pooled 2,148 patients fix TILs as the strongest early progno...","from":"tnbc","refs":["paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019","paper-loi-tils-pooled-early-tnbc-jco-2019"]},{"group":"history","date":"2019","precision":"year","title":"PRIMA and PAOLA-1 extend PARP maintenance beyond BRCA","note":"High-grade serous ovarian cancer","from":"high-grade-serous-ovarian-cancer","refs":["prima","paola-1"]},{"group":"history","date":"2019","precision":"year","title":"PRIMA and PAOLA-1 extend PARP maintenance to HRD-positive and all-comer populations","note":"Platinum-sensitive ovarian cancer","from":"platinum-sensitive-ovarian-cancer","refs":["prima","paola-1"]},{"group":"history","date":"2019","precision":"year","title":"Rare but real: microsatellite instability, and PSMA PET measured properly","note":"Prostate cancer. Microsatellite instability-high or mismatch repair deficient disease is found in 3.1% of 1,033 men, with durable checkpoint inhibitor responses in 6 of 11 treated...","from":"prostate","refs":["paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019","paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019","paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019","psma"]},{"group":"history","date":"2019","precision":"year","title":"Regorafenib (SARC024, REGOBONE) and cabozantinib (CABONE) show activity at relapse","note":"Osteosarcoma","from":"osteosarcoma","refs":["regorafenib","cabozantinib"]},{"group":"history","date":"2019","precision":"year","title":"Response-adapted treatment of SNUC","note":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma). Amit and colleagues, JAMA Oncol.","from":"sinonasal","refs":["cisplatin","etoposide"]},{"group":"history","date":"2019","precision":"year","title":"Ropeginterferon alfa-2b approved in Europe","note":"Polycythaemia vera (PV). The first interferon licensed for PV, on PROUD-PV and CONTINUATION-PV; FDA approval followed in November 2021.","from":"polycythaemia-vera","refs":["ropeginterferon-alfa-2b","proud-pv"]},{"group":"history","date":"2019","precision":"year","title":"Rovalpituzumab tesirine (first DLL3 ADC) fails","note":"Small-cell lung cancer","from":"sclc","refs":["dll3"]},{"group":"history","date":"2019","precision":"year","title":"RTOG 1016 and De-ESCALaTE: cetuximab inferior to cisplatin","note":"Oropharyngeal cancer (tonsil and base of tongue)","from":"oropharyngeal-cancer","refs":["rtog-1016","de-escalate"]},{"group":"history","date":"2019","precision":"year","title":"RTOG 1016 and De-ESCALaTE: cetuximab inferior to cisplatin","note":"HPV-positive oropharyngeal cancer","from":"hpv-positive-oropharyngeal-cancer","refs":["rtog-1016","de-escalate"]},{"group":"history","date":"2019","precision":"year","title":"SABR-COMET reports","note":"Metastatic cancer (cancer that has spread). Randomised phase 2 trial in which stereotactic radiotherapy to all sites of oligometastatic disease was associated with longer survival...","from":"metastatic-cancer","refs":["sbrt"]},{"group":"history","date":"2019","precision":"year","title":"Selumetinib active in recurrent pLGG","note":"Paediatric low-grade glioma. PBTC-029 phase 2 (Fangusaro, Lancet Oncology) reports responses in BRAF-altered and NF1-associated tumours.","from":"paediatric-low-grade-glioma","refs":[]},{"group":"history","date":"2019","precision":"year","title":"STRASS2 opens: neoadjuvant chemotherapy versus surgery alone","note":"Retroperitoneal sarcoma","from":"retroperitoneal-sarcoma","refs":["doxorubicin","ifosfamide"]},{"group":"history","date":"2019","precision":"year","title":"T-DXd approved; HER2CLIMB proves CNS benefit","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["trastuzumab-deruxtecan","her2climb"]},{"group":"history","date":"2019","precision":"year","title":"Tagraxofusp NEJM pivotal data (Pemmaraju)","note":"Blastic plasmacytoid dendritic cell neoplasm (BPDCN)","from":"bpdcn","refs":["tagraxofusp"]},{"group":"history","date":"2019","precision":"year","title":"The bowel lining is already mutated","note":"Colorectal cancer. About 1% of morphologically normal colorectal crypts in middle age carry a probable driver mutation, so adenomas and cancers are the rare outcomes of a process h...","from":"colorectal","refs":["paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019"]},{"group":"history","date":"2019","precision":"year","title":"TITAN, ENZAMET and ARCHES: androgen receptor inhibitors for all","note":"Metastatic hormone-sensitive prostate cancer","from":"prostate-mhspc","refs":["arches","apalutamide","enzalutamide"]},{"group":"history","date":"2019","precision":"year","title":"Toripalimab plus axitinib phase 1b reports responses in nearly half","note":"Mucosal melanoma","from":"mucosal-melanoma","refs":["toripalimab","axitinib"]},{"group":"history","date":"2019","precision":"year","title":"Trastuzumab with docetaxel: phase 2 response rate 70.2 percent","note":"Salivary duct carcinoma","from":"salivary-duct-carcinoma","refs":["trastuzumab","docetaxel"]},{"group":"history","date":"2019","precision":"year","title":"Trastuzumab-docetaxel in HER2+ salivary duct carcinoma (Takahashi, JCO); lenvatinib in ACC (Tchekmedyian, JCO)","note":"Salivary gland cancers","from":"salivary-gland","refs":["trastuzumab","docetaxel","lenvatinib"]},{"group":"history","date":"2019","precision":"year","title":"TTFields device approval (HDE) on STELLAR","note":"Mesothelioma","from":"mesothelioma","refs":["stellar","optune"]},{"group":"history","date":"2019","precision":"year","title":"Vemurafenib in refractory childhood LCH","note":"Langerhans cell histiocytosis (LCH). Donadieu and colleagues (JCO) report responses in nearly all BRAF V600E children, with reactivation after stopping.","from":"langerhans-cell-histiocytosis","refs":["vemurafenib"]},{"group":"history","date":"2019","precision":"year","title":"Vemurafenib reported to produce responses in refractory BRAF-mutant children","note":"Multisystem Langerhans cell histiocytosis (with or without risk-organ involvement)","from":"lch-multisystem","refs":["vemurafenib"]},{"group":"history","date":"2019","precision":"year","title":"WHO classification of breast tumours, 5th edition","note":"Triple-negative breast cancer (TNBC). Medullary carcinoma becomes a pattern of invasive carcinoma of no special type; metaplastic, adenoid cystic, apocrine and secretory carcinomas...","from":"tnbc","refs":["medullary-pattern-breast-carcinoma","metaplastic-breast-carcinoma"]},{"group":"history","date":"2019","precision":"year","title":"WHO classification of breast tumours, 5th edition","note":"Breast cancer (all types). Keeps invasive carcinoma of no special type as the default group and folds the former medullary, oncocytic, lipid-rich, glycogen-rich, sebaceous and pleo...","from":"breast-cancer","refs":["who-breast-classification"]},{"group":"history","date":"2019","precision":"year","title":"WHO classification of digestive tumours, 5th edition","note":"Pancreatic ductal adenocarcinoma. Adenosquamous, colloid and undifferentiated carcinomas and the IPMN- and MCN-associated carcinomas listed as variants of ductal adenocarcinoma; so...","from":"pancreatic","refs":["pancreatic-adenosquamous-carcinoma","pancreatic-colloid-carcinoma","pancreatic-undifferentiated-carcinoma-ogc","solid-pseudopapillary-neoplasm"]},{"group":"history","date":"2019","precision":"year","title":"WHO classification, 5th edition","note":"Gallbladder cancer. The digestive system volume standardises the nomenclature of gallbladder carcinoma and its precursors (biliary intraepithelial neoplasia, intracholecystic papil...","from":"gallbladder","refs":["gallbladder-carcinoma-in-situ-and-dysplasia"]},{"group":"history","date":"2019","precision":"year","title":"WHO digestive system classification extends NET G3 to the whole gut","note":"Grade 3 well-differentiated neuroendocrine tumour","from":"grade-3-net","refs":["net-grade-ki67"]},{"group":"history","date":"2019","precision":"year","title":"WHO digestive system classification: grade 3 tumour and carcinoma become distinct entities","note":"Extrapulmonary neuroendocrine carcinoma","from":"extrapulmonary-nec","refs":["net-grade-ki67"]},{"group":"history","date":"2019","precision":"year","title":"WHO renames the tumour goblet cell adenocarcinoma with a three-tier grade","note":"Goblet cell adenocarcinoma of the appendix","from":"goblet-cell-adenocarcinoma","refs":[]},{"group":"history","date":"2019","precision":"year","title":"Zanubrutinib approved","note":"Mantle cell lymphoma","from":"mantle-cell-lymphoma","refs":["zanubrutinib"]},{"group":"journal","date":"2019","precision":"year","title":"JCO global oncology founded","note":"American Society of Clinical Oncology","from":"jco-global-oncology","refs":[]},{"group":"journal","date":"2019","precision":"year","title":"Journal of breast imaging founded","note":"Oxford University Press","from":"journal-of-breast-imaging","refs":[]},{"group":"journal","date":"2019","precision":"year","title":"medRxiv founded","note":"Cold Spring Harbor Laboratory, BMJ and Yale University","from":"medrxiv","refs":[]},{"group":"journal","date":"2019","precision":"year","title":"NAR cancer founded","note":"Oxford University Press","from":"nar-cancer","refs":[]},{"group":"journal","date":"2019","precision":"year","title":"Radiology. Imaging cancer founded","note":"Radiological Society of North America","from":"radiology-imaging-cancer","refs":[]},{"group":"journal","date":"2019","precision":"year","title":"The Lancet Digital Health founded","note":"Elsevier","from":"lancet-digital-health","refs":[]},{"group":"law","date":"2019","precision":"year","title":"China Drug Administration Law (2019) and expedited pathways","note":"China, statute.","from":"china-drug-administration-law","refs":[]},{"group":"law","date":"2019","precision":"year","title":"China Human Genetic Resources rules (2019, 2023)","note":"China, regulation.","from":"china-hgr-rules","refs":[]},{"group":"law","date":"2019","precision":"year","title":"India New Drugs and Clinical Trials Rules 2019","note":"India, regulation.","from":"india-new-drugs-rules-2019","refs":[]},{"group":"law","date":"2019","precision":"year","title":"Project Orbis","note":"International, scheme.","from":"project-orbis","refs":[]},{"group":"law","date":"2019","precision":"year","title":"Tobacco 21","note":"United States, statute.","from":"tobacco-21","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-...","note":"Earl HM, Hiller L, Vallier AL, et al. The Lancet.","from":"paper-persephone-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"68 Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer","note":"Kratochwil C, Flechsig P, Lindner T, et al. Journal of Nuclear Medicine.","from":"paper-kratochwil-j-nucl-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer","note":"Hugosson J, Roobol MJ, Månsson M, et al. European Urology.","from":"paper-hugosson-eur-urol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial","note":"Yan Z, Cao J, Cheng H, et al. The Lancet Haematology.","from":"paper-cd19-multiple-myeloma-lancet-haematol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesoph...","note":"Türeci O, Sahin U, Schulze-Bergkamen H, et al. Annals of Oncology.","from":"paper-peter-thuss-patience-ann-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","note":"Stock W, Luger SM, Advani AS, et al. Blood.","from":"paper-stock-blood","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus chemoradiotherapy) in locally advanced gallbladder cancers (POLC...","note":"Engineer R, Patkar S, Lewis SC, et al. BMJ Open.","from":"paper-polcagb-protocol-bmj-open-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"A view on drug resistance in cancer","note":"Vasan N, Baselga J, Hyman DM. Nature.","from":"paper-vasan-nature","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall surviva...","note":"Fizazi K, Tran N, Fein L, et al. The Lancet Oncology.","from":"paper-latitude-lancet-oncol-2019-update","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Accuracy of gallium-68 PSMA-11 PET in localising recurrent prostate cancer: a prospective single-arm clinical trial","note":"Fendler WP, Calais J, Eiber M, et al. JAMA Oncology.","from":"paper-fendler-psma-pet-biochemical-recurrence-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ACNS0121: conformal radiotherapy for paediatric ependymoma, chemotherapy for incompletely resected tumours and observation after complete resection","note":"Merchant TE, Bendel AE, Sabin ND, et al. Journal of Clinical Oncology.","from":"paper-acns0121-ependymoma-conformal-radiotherapy-merchant-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ACNS1123: response-based reduced radiotherapy for localised CNS non-germinomatous germ cell tumours","note":"Fangusaro J, Wu S, MacDonald S, et al. Journal of Clinical Oncology.","from":"paper-acns1123-nggct-reduced-radiotherapy-fangusaro-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms","note":"Durham BH, Lopez Rodrigo E, Picarsic J, et al. Nature Medicine.","from":"paper-durham-nat-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ADMIRAL: gilteritinib pills versus chemotherapy for relapsed FLT3-mutated acute myeloid leukaemia","note":"Perl AE, Martinelli G, Cortes JE, et al. New England Journal of Medicine.","from":"paper-admiral-gilteritinib-flt3-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Advances in Auto-Segmentation","note":"Cardenas CE, Yang J, Anderson BM, et al. Seminars in radiation oncology.","from":"paper-cardenas-semin-radiat-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","note":"Shaw AT, Solomon BJ, Besse B, et al. Journal of Clinical Oncology.","from":"paper-shaw-alk-resistance-mutations-lorlatinib-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"An Observational Study of Deep Learning and Automated Evaluation of Cervical Images for Cancer Screening","note":"Hu L, Bell D, Antani S, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-hu-j-natl-cancer-inst","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","note":"Reinert T, Henriksen TV, Christensen E, et al. JAMA Oncology.","from":"paper-reinert-ctdna-ultradeep-sequencing-colorectal-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ANBL0531: response- and biology-based therapy for intermediate-risk neuroblastoma","note":"Twist CJ, Schmidt ML, Naranjo A, et al. Journal of Clinical Oncology.","from":"paper-anbl0531-twist-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ANBL0532: tandem versus single autologous stem cell transplant for high-risk neuroblastoma","note":"Park JR, Kreissman SG, London WB, et al. JAMA.","from":"paper-anbl0532-tandem-transplant-park-jama-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Anlotinib for Refractory Advanced Non-Small Cell Lung Cancer in China","note":"Chen XZ. JAMA Oncology.","from":"paper-chen-jama-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer","note":"Chi KN, Agarwal N, Bjartell A, et al. New England Journal of Medicine.","from":"paper-nct02489318-n-engl-j-med-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer","note":"Fizazi K, Shore N, Tammela TL, et al. New England Journal of Medicine.","from":"paper-aramis-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer","note":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, et al. Journal of Clinical Oncology.","from":"paper-arches-j-clin-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Are 90% of deaths from cancer caused by metastases?","note":"Dillekås H, Rogers MS, Straume O. Cancer medicine.","from":"paper-dillekas-cancer-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Assessment of molecular relapse detection in early-stage breast cancer","note":"Garcia-Murillas I, Chopra N, Comino-Mendez I, et al. JAMA Oncology.","from":"paper-garcia-murillas-molecular-relapse-detection-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval","note":"Gyawali B, Hey SP, Kesselheim AS. JAMA Internal Medicine.","from":"paper-gyawali-jama-intern-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Association of Black race with prostate cancer-specific and other-cause mortality","note":"Dess RT, Hartman HE, Mahal BA, et al. JAMA Oncology.","from":"paper-dess-black-race-prostate-mortality-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","note":"Lee DW, Santomasso BD, Locke FL, et al. Biology of blood and marrow transplantation.","from":"paper-lee-biol-blood-marrow-transplant","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370)","note":"Eng C, Kim TW, Bendell J, et al. Lancet Oncology.","from":"paper-eng-imblaze370-atezolizumab-cobimetinib-colorectal-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","note":"Leonard JP, Trneny M, Izutsu K, et al. Journal of Clinical Oncology.","from":"paper-augment-lenalidomide-rituximab-leonard-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Stu...","note":"Dix DB, Fernandez CV, Chi YY, et al. Journal of Clinical Oncology.","from":"paper-dix-j-clin-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"BILCAP: capecitabine compared with observation in resected biliary tract cancer","note":"Primrose JN, Fox RP, Palmer DH, et al. The Lancet Oncology.","from":"paper-bilcap-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Blood-Brain Barrier Opening in Primary Brain Tumors with Non-invasive MR-Guided Focused Ultrasound: A Clinical Safety and Feasibility Study","note":"Mainprize T, Lipsman N, Huang Y, et al. Scientific reports.","from":"paper-mainprize-sci-rep","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Brain metastases","note":"Achrol AS, Rennert RC, Anders C, et al. Nature reviews. Disease primers.","from":"paper-achrol-nat-rev-dis-primers","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Breast cancer","note":"Harbeck N, Penault-Llorca F, Cortes J, et al. Nature reviews. Disease primers.","from":"paper-harbeck-nat-rev-dis-primers","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","note":"Horwitz S, O'Connor OA, Pro B, et al. The Lancet.","from":"paper-horwitz-lancet","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Cannabis Impacts Tumor Response Rate to Nivolumab in Patients with Advanced Malignancies","note":"Taha T, Meiri D, Talhamy S, et al. The oncologist.","from":"paper-taha-oncologist","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Carcinogenicity of night shift work","note":"IARC Monographs Vol 124 group. The Lancet Oncology.","from":"paper-iarc-monographs-vol-124-group-lancet-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"CASSIOPEIA: daratumumab added to bortezomib, thalidomide and dexamethasone before and after transplant in newly diagnosed myeloma","note":"Moreau P, Attal M, Hulin C, et al. The Lancet.","from":"paper-cassiopeia-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Changes in gallbladder cancer mortality and hospital discharges due to preventive cholecystectomy in Chile","note":"Mardones ML, Frenz P. Revista Medica de Chile.","from":"paper-mardones-frenz-chile-ges-mortality-rev-med-chile-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer","note":"Bernard V, Kim DU, San Lucas FA, et al. Gastroenterology.","from":"paper-bernard-ctdna-exodna-pancreatic-gastroenterology-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Circulating tumor DNA as a clinical test in resected pancreatic cancer","note":"Groot VP, Mosier S, Javed AA, et al. Clinical Cancer Research.","from":"paper-groot-kras-ctdna-clinical-test-resected-pancreatic-ccr-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer","note":"Lee B, Lipton L, Cohen J, et al. Annals of Oncology.","from":"paper-lee-ctdna-adjuvant-benefit-localized-pancreatic-ann-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Circulating tumor DNA profiling of advanced biliary tract cancers","note":"Mody K, Kasi PM, Yang J, et al. JCO Precision Oncology.","from":"paper-mody-biliary-ctdna-profiling-jco-po-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer","note":"Aggarwal C, Thompson JC, Black TA, et al. JAMA Oncology.","from":"paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","note":"Fischer K, Al-Sawaf O, Bahlo J, et al. New England Journal of Medicine.","from":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Clonal hematopoiesis in human aging and disease","note":"Jaiswal S, Ebert BL. Science.","from":"paper-jaiswal-science","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Colorectal cancer","note":"Dekker E, Tanis PJ, Vleugels JLA, et al. The Lancet.","from":"paper-dekker-lancet","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","note":"Rotte A. Journal of experimental & clinical cancer research.","from":"paper-ctla-4-colorectal-j-exp-clin-cancer-res-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen","note":"Menden MP, Wang D, Mason MJ, et al. Nature Communications.","from":"paper-menden-nat-commun","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes","note":"Offin M, Chan JM, Tenet M, et al. Journal of Thoracic Oncology.","from":"paper-offin-rb1-tp53-transformation-risk-jto-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Context-dependent roles of complement in cancer","note":"Roumenina LT, Daugan MV, Petitprez F, et al. Nature Reviews Cancer.","from":"paper-roumenina-nat-rev-cancer","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts","note":"Elyada E, Bolisetty M, Laise P, et al. Cancer Discovery.","from":"paper-elyada-antigen-presenting-cafs-single-cell-cancer-discov-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"De-ESCALaTE HPV: radiotherapy plus cisplatin or cetuximab in low-risk HPV-positive oropharyngeal cancer","note":"Mehanna H, Robinson M, Hartley A, et al. The Lancet.","from":"paper-de-escalate-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","note":"Dudley JC, Schroers-Martin J, Lazzareschi DV, et al. Cancer Discovery.","from":"paper-dudley-cancer-discov","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Detection of individual prostate cancer foci via multiparametric magnetic resonance imaging","note":"Johnson DC, Raman SS, Mirak SA, et al. European Urology.","from":"paper-johnson-mpmri-individual-foci-eur-urol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Detection of NRG1 gene fusions in solid tumors","note":"Jonna S, Feldman RA, Swensen J, et al. Clinical Cancer Research.","from":"paper-jonna-nrg1-fusions-solid-tumours-ccr-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018","note":"Loree JM, Anand S, Dasari A, et al. JAMA Oncology.","from":"paper-loree-jama-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","note":"Paz-Ares L, Dvorkin M, Chen Y, et al. The Lancet.","from":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial","note":"O'Reilly EM, Oh DY, Dhani N, et al. JAMA Oncology.","from":"paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The S...","note":"Ng K, Nimeiri HS, McCleary NJ, et al. JAMA.","from":"paper-ng-jama","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Ran...","note":"Hoskin PJ, Hopkins K, Misra V, et al. JAMA.","from":"paper-hoskin-jama","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Effect of True and Sham Acupuncture on Radiation-Induced Xerostomia Among Patients With Head and Neck Cancer: A Randomized Clinical Trial","note":"Garcia MK, Meng Z, Rosenthal DI, et al. JAMA network open.","from":"paper-garcia-jama-netw-open","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in...","note":"Boevé LMS, Hulshof MCCM, Vis AN, et al. European Urology.","from":"paper-boeve-eur-urol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","note":"Pryma DA, Chin BB, Noto RB, et al. Journal of Nuclear Medicine.","from":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study","note":"Chung HC, Ros W, Delord JP, et al. Journal of Clinical Oncology.","from":"paper-keynote-158-j-clin-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 stud...","note":"Duffaud F, Mir O, Boudou-Rouquette P, et al. The Lancet Oncology.","from":"paper-florence-duffaud-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From...","note":"Morgensztern D, Besse B, Greillier L, et al. Clinical Cancer Research.","from":"paper-dll3-sclc-clin-cancer-res-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Efficacy of MEK inhibition in patients with histiocytic neoplasms","note":"Diamond EL, Durham BH, Ulaner GA, et al. Nature.","from":"paper-diamond-nature","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"EGFR-mutant adenocarcinomas that transform to small-cell lung cancer and other neuroendocrine carcinomas: clinical outcomes","note":"Marcoux N, Gettinger SN, O'Kane G, et al. Journal of Clinical Oncology.","from":"paper-marcoux-egfr-small-cell-transformation-outcomes-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Electrical and synaptic integration of glioma into neural circuits","note":"Venkatesh HS, Morishita W, Geraghty AC, et al. Nature.","from":"paper-venkatesh-nature","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON CRC)","note":"Kopetz S, Grothey A, Yaeger R, et al. New England Journal of Medicine.","from":"paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer","note":"Davis ID, Martin AJ, Stockler MR, et al. New England Journal of Medicine.","from":"paper-enzamet-n-engl-j-med-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Enzyme replacement improves survival among patients with pancreatic cancer: Results of a population based study","note":"Roberts KJ, Bannister CA, Schrem H. Pancreatology.","from":"paper-roberts-pert-survival-pancreatic-cancer-pancreatology-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Epidemiology of gallbladder cancer in India","note":"Dutta U, Bush N, Kalsi D, Popli P, Kapoor VK. Chinese Clinical Oncology.","from":"paper-dutta-gallbladder-cancer-epidemiology-india-chin-clin-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Estimation of clinical trial success rates and related parameters","note":"Wong CH, Siah KW, Lo AW. Biostatistics (Oxford, England).","from":"paper-wong-biostatistics","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs","note":"Haslam A, Prasad V. JAMA network open.","from":"paper-haslam-jama-netw-open","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"European LeukemiaNet recommendations for the management of acute promyelocytic leukaemia (2019 update)","note":"Sanz MA, Sanz MA, Fenaux P, et al. Blood.","from":"paper-eln-apl-sanz-blood-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers","note":"Aldrich MC, Mercaldo SF, Sandler KL, et al. JAMA Oncology.","from":"paper-aldrich-uspstf-screening-african-american-smokers-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable","note":"Campbell KL, Winters-Stone KM, Wiskemann J, et al. Medicine and science in sports and exercise.","from":"paper-campbell-med-sci-sports-exerc","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Ferlay 2019: GLOBOCAN 2018 sources and methods","note":"Ferlay J, Colombet M, Soerjomataram I, et al. International Journal of Cancer.","from":"paper-ferlay-globocan-2018-methods-ijc-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"First Human Imaging Studies with the EXPLORER Total-Body PET Scanner","note":"Badawi RD, Shi H, Hu P, et al. Journal of Nuclear Medicine.","from":"paper-badawi-j-nucl-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"FLOT4-AIO: perioperative FLOT versus ECF/ECX for resectable gastric or gastro-oesophageal junction adenocarcinoma","note":"Al-Batran SE, Homann N, Pauligk C, et al. The Lancet.","from":"paper-flot4-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma","note":"Zhang Y, Chen L, Hu GQ, et al. New England Journal of Medicine.","from":"paper-zhang-gemcitabine-cisplatin-induction-nasopharyngeal-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial","note":"Shroff RT, Javle MM, Xiao L, et al. JAMA Oncology.","from":"paper-gap-phase2-mdacc-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","note":"Jiang YZ, Ma D, Suo C, et al. Cancer Cell.","from":"paper-jiang-fuscc-tnbc-landscape-cancer-cell-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial","note":"Rodon J, Soria JC, Berger R, et al. Nature Medicine.","from":"paper-rodon-nat-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Genomic characterization of metastatic breast cancers","note":"Bertucci F, Ng CKY, Patsouris A, et al. Nature.","from":"paper-bertucci-metastatic-breast-genomics-nature-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Genomic correlates of clinical outcome in advanced prostate cancer","note":"Abida W, Cyrta J, Heller G, et al. Proceedings of the National Academy of Sciences.","from":"paper-abida-genomic-correlates-outcome-mcrpc-pnas-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","note":"Ettrich TJ, Schwerdel D, Dolnik A, et al. Scientific Reports.","from":"paper-ettrich-cholangiocarcinoma-ctdna-genotyping-sci-rep-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","note":"Yurgelun MB, Chittenden AB, Morales-Oyarvide V, et al. Genetics in Medicine.","from":"paper-yurgelun-germline-second-hits-resected-pancreatic-genet-med-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Glioblastoma Treated With Magnetic Resonance Imaging-Guided Laser Interstitial Thermal Therapy: Safety, Efficacy, and Outcomes","note":"Kamath AA, Friedman DD, Akbari SHA, et al. Neurosurgery.","from":"paper-kamath-neurosurgery","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Glutamatergic synaptic input to glioma cells drives brain tumour progression","note":"Venkataramani V, Tanev DI, Strahle C, et al. Nature.","from":"paper-venkataramani-nature","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Hair disorders in cancer survivors","note":"Freites-Martinez A, Shapiro J, van den Hurk C, et al. Journal of the American Academy of Dermatology.","from":"paper-freites-martinez-j-am-acad-dermatol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets","note":"Cassetta L, Fragkogianni S, Sims AH, et al. Cancer Cell.","from":"paper-shelley-hwang-cancer-cell-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB/SWOG 80405","note":"Lenz HJ, Ou FS, Venook AP, et al. Journal of Clinical Oncology.","from":"paper-lenz-cms-calgb-swog-80405-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years","note":"Vuik FE, Nieuwenburg SA, Bardou M, et al. Gut.","from":"paper-vuik-early-onset-colorectal-europe-gut-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early...","note":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG). The Lancet.","from":"paper-early-breast-cancer-trialists-collaborative-group-ebctcg-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Individual patient data meta-analysis of microsatellite instability as a biomarker in gastric cancer (MAGIC, CLASSIC, ARTIST, ITACA-S)","note":"Pietrantonio F, Miceli R, Raimondi A, et al. Journal of Clinical Oncology.","from":"paper-pietrantonio-msi-gastric-meta-analysis-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Individualised nutritional support in medical inpatients at nutritional risk: a randomised clinical trial","note":"Schuetz P, Fehr R, Baechli V, et al. The Lancet.","from":"paper-schuetz-lancet","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Induction chemotherapy response as a guide to treatment optimisation in sinonasal undifferentiated carcinoma","note":"Amit M, Abdelmeguid AS, Watcherporn T, et al. Journal of Clinical Oncology.","from":"paper-amit-induction-chemotherapy-response-snuc-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Inflammation and Cancer: Triggers, Mechanisms, and Consequences","note":"Greten FR, Grivennikov SI. Immunity.","from":"paper-greten-immunity","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Intensified therapies improve survival and identification of novel prognostic factors for placental-site and epithelioid trophoblastic tumours","note":"Froeling FEM, Ramaswami R, Papanastasopoulos P, et al. British Journal of Cancer.","from":"paper-froeling-pstt-ett-intensified-therapy-bjc-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international...","note":"Brand DH, Tree AC, Ostler P, et al. The Lancet Oncology.","from":"paper-pace-b-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Interfant-06: outcome of infants under one year with acute lymphoblastic leukaemia","note":"Pieters R, De Lorenzo P, Ancliffe P, et al. Journal of Clinical Oncology.","from":"paper-interfant-06-pieters-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Jones 2019: NRG1 gene fusions are recurrent, clinically actionable rearrangements in KRAS wild-type pancreatic ductal adenocarcinoma","note":"Jones MR, Williamson LM, Topham JT, et al. Clinical Cancer Research.","from":"paper-jones-nrg1-fusions-recurrent-actionable-kras-wild-type-pdac-ccr-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"JULIET: tisagenlecleucel for adults with relapsed or refractory diffuse large B-cell lymphoma","note":"Schuster SJ, Bishop MR, Tam CS, et al. New England Journal of Medicine.","from":"paper-juliet-tisagenlecleucel-dlbcl-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment","note":"von Minckwitz G, Huang CS, Mano MS, et al. New England Journal of Medicine.","from":"paper-katherine-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"KEYNOTE-048: pembrolizumab, alone or with chemotherapy, as first treatment for recurrent or metastatic head and neck cancer","note":"Burtness B, Harrington KJ, Greil R, et al. The Lancet.","from":"paper-keynote-048-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","note":"Armand P, Rodig S, Melnichenko V, et al. Journal of Clinical Oncology.","from":"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma","note":"Rini BI, Plimack ER, Stus V, et al. New England Journal of Medicine.","from":"paper-keynote-426-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"KLASS-01: laparoscopic versus open distal gastrectomy for stage I gastric cancer, long-term survival","note":"Kim HH, Han SU, Kim MC, et al. JAMA Oncology.","from":"paper-klass-01-kim-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equiva...","note":"Vicini FA, Cecchini RS, White JR, et al. The Lancet.","from":"paper-nsabp-b39-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Macrophages as regulators of tumour immunity and immunotherapy","note":"DeNardo DG, Ruffell B. Nature reviews. Immunology.","from":"paper-denardo-nat-rev-immunol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant","note":"Facon T, Kumar S, Plesner T, et al. New England Journal of Medicine.","from":"paper-maia-daratumumab-rd-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update","note":"Bohlius J, Bohlke K, Castelli R, et al. Journal of Clinical Oncology.","from":"paper-bohlius-j-clin-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Mindfulness-based interventions for psychological and physical health outcomes in cancer patients and survivors: A systematic review and meta-analysis of random...","note":"Cillessen L, Johannsen M, Speckens AEM, et al. Psycho-oncology.","from":"paper-cillessen-psychooncology","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma","note":"Goeppert B, Roessler S, Renner M, et al. British Journal of Cancer.","from":"paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","note":"Weinberg BA, Xiu J, Lindberg MR, et al. Journal of Gastrointestinal Oncology.","from":"paper-weinberg-biliary-profiling-jgo-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study","note":"Sicklick JK, Kato S, Okamura R, et al. Nature Medicine.","from":"paper-sicklick-nat-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","note":"Labrecque MP, Coleman IM, Brown LG, et al. Journal of Clinical Investigation.","from":"paper-labrecque-mcrpc-phenotypes-jci-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","note":"Rudin CM, Poirier JT, Byers LA, et al. Nature Reviews Cancer.","from":"paper-rudin-sclc-molecular-subtypes-nat-rev-cancer-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Mucinous ovarian carcinoma (review)","note":"Morice P, Gouy S, Leary A. New England Journal of Medicine.","from":"paper-morice-mucinous-ovarian-carcinoma-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sar...","note":"Bonvalot S, Rutkowski PL, Thariat J, et al. The Lancet Oncology.","from":"paper-act-in-sarc-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"NILE: clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung ca...","note":"Leighl NB, Page RD, Raymond VM, et al. Clinical Cancer Research.","from":"paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","note":"Hellmann MD, Paz-Ares L, Bernabe Caro R, et al. New England Journal of Medicine.","from":"paper-keunchil-park-n-engl-j-med-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"NRG Oncology RTOG 1016: radiotherapy plus cetuximab versus cisplatin in HPV-positive oropharyngeal cancer","note":"Gillison ML, Trotti AM, Harris J, et al. The Lancet.","from":"paper-rtog-1016-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation...","note":"Robson ME, Tung N, Conte P, et al. Annals of Oncology.","from":"paper-olympiad-ann-oncol-2019-update","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with ext...","note":"Rugo HS, Finn RS, Diéras V, et al. Breast cancer research and treatment.","from":"paper-paloma-2-breast-cancer-res-treat-2019-update","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"PAOLA-1: olaparib added to bevacizumab maintenance in newly diagnosed ovarian cancer, with benefit confined to HRD-positive tumours","note":"Ray-Coquard I, Pautier P, Pignata S, et al. New England Journal of Medicine.","from":"paper-paola-1-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Pathways of progression from intraductal papillary mucinous neoplasm to pancreatic ductal adenocarcinoma based on molecular features","note":"Omori Y, Ono Y, Tanino M, et al. Gastroenterology.","from":"paper-omori-ipmn-progression-pathways-gastroenterology-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomi...","note":"Mok TSK, Wu YL, Kudaba I, et al. The Lancet.","from":"paper-keynote-042-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-l...","note":"Cohen EEW, Soulières D, Le Tourneau C, et al. The Lancet.","from":"paper-jean-pascal-machiels-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple ba...","note":"Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. The Lancet Oncology.","from":"paper-mypathway-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial","note":"Tap WD, Gelderblom H, Palmerini E, et al. The Lancet.","from":"paper-tap-lancet","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Phase 2 study of lenvatinib in progressive, recurrent or metastatic adenoid cystic carcinoma","note":"Tchekmedyian V, Sherman EJ, Dunn L, et al. Journal of Clinical Oncology.","from":"paper-tchekmedyian-lenvatinib-adenoid-cystic-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Phase 2 trial of trastuzumab and docetaxel in HER2-positive salivary duct carcinoma","note":"Takahashi H, Tada Y, Saotome T, et al. Journal of Clinical Oncology.","from":"paper-takahashi-trastuzumab-docetaxel-salivary-duct-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177 Lu-Satoreotide Tetraxetan","note":"Reidy-Lagunes D, Pandit-Taskar N, O'Donoghue JA, et al. Clinical Cancer Research.","from":"paper-reidy-lagunes-clin-cancer-res","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"POLO: maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","note":"Golan T, Hammel P, Reni M, et al. New England Journal of Medicine.","from":"paper-polo-olaparib-maintenance-gbrca-pancreatic-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes","note":"Mavaddat N, Michailidou K, Dennis J, et al. American journal of human genetics.","from":"paper-mavaddat-am-j-hum-genet","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Polyp size of 1 cm is insufficient to discriminate neoplastic and non-neoplastic gallbladder polyps","note":"Wennmacker SZ, van Dijk AH, Raessens JHJ, et al. Surgical Endoscopy.","from":"paper-wennmacker-gallbladder-polyp-size-threshold-surg-endosc-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update","note":"Khorana AA, McKernin SE, Berlin J, et al. Journal of Clinical Oncology.","from":"paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications","note":"Alyami M, Hübner M, Grass F, et al. The Lancet Oncology.","from":"paper-alyami-lancet-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines","note":"Nicolosi P, Ledet E, Yang S, et al. JAMA Oncology.","from":"paper-nicolosi-germline-variants-prostate-testing-guidelines-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade","note":"Abida W, Cheng ML, Armenia J, et al. JAMA Oncology.","from":"paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"PRIMA: niraparib maintenance in newly diagnosed advanced ovarian cancer","note":"González-Martín A, Pothuri B, Vergote I, et al. New England Journal of Medicine.","from":"paper-prima-niraparib-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy","note":"Park JH, Jonas SF, Bataillon G, et al. Annals of Oncology.","from":"paper-park-tils-untreated-early-tnbc-ann-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"PROPHECY: prospective multicentre validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate can...","note":"Armstrong AJ, Halabi S, Luo J, et al. Journal of Clinical Oncology.","from":"paper-prophecy-arv7-validation-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Prospective comprehensive genomic profiling of 3,476 primary and metastatic prostate tumours","note":"Chung JH, Dewal N, Sokol E, et al. JCO Precision Oncology.","from":"paper-chung-comprehensive-genomic-profiling-prostate-jco-po-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial","note":"Nichols AC, Theurer J, Prisman E, et al. The Lancet Oncology.","from":"paper-anthony-nichols-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled...","note":"Nakagawa K, Garon EB, Seto T, et al. The Lancet Oncology.","from":"paper-nct02411448-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Randomised phase 2 trial of site-specific treatment based on gene expression profiling versus carboplatin and paclitaxel in cancer of unknown primary","note":"Hayashi H, Kurata T, Takiguchi Y, et al. Journal of Clinical Oncology.","from":"paper-hayashi-site-specific-vs-empirical-chemotherapy-cup-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or use...","note":"Singhi AD, George B, Greenbowe JR, et al. Gastroenterology.","from":"paper-singhi-targeted-genome-profiling-3594-pdac-gastroenterology-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Regional differences in gallbladder cancer pathogenesis: insights from a multi-institutional comparison of tumor mutations","note":"Narayan RR, Creasy JM, Goldman DA, et al. Cancer.","from":"paper-narayan-gallbladder-regional-mutations-cancer-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer","note":"Bardia A, Mayer IA, Vahdat LT, et al. New England Journal of Medicine.","from":"paper-sacituzumab-govitecan-tnbc-n-engl-j-med-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results From the Phase I/II CheckMate 358 Trial","note":"Naumann RW, Hollebecque A, Meyer T, et al. Journal of Clinical Oncology.","from":"paper-checkmate-358-j-clin-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Safety and Feasibility of Repeated and Transient Blood-Brain Barrier Disruption by Pulsed Ultrasound in Patients with Recurrent Glioblastoma","note":"Idbaih A, Canney M, Belin L, et al. Clinical Cancer Research.","from":"paper-idbaih-clin-cancer-res","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Siegel 2019: Cancer statistics, 2019","note":"Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-cancer-statistics-2019-cacancer-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"SOLAR-1: alpelisib plus fulvestrant for PIK3CA-mutated hormone receptor-positive advanced breast cancer","note":"André F, Ciruelos E, Rubovszky G, et al. New England Journal of Medicine.","from":"paper-solar-1-alpelisib-nejm-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers","note":"Gruosso T, Gigoux M, Manem VSK, et al. Journal of Clinical Investigation.","from":"paper-gruosso-tnbc-spatial-immune-microenvironments-jci-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, op...","note":"Palma DA, Olson R, Harrow S, et al. The Lancet.","from":"paper-sabr-comet-lancet-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised con...","note":"Ball D, Mai GT, Vinod S, et al. The Lancet Oncology.","from":"paper-chisel-lancet-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Supplemental MRI Screening for Women with Extremely Dense Breast Tissue","note":"Bakker MF, de Lange SV, Pijnappel RM, et al. New England Journal of Medicine.","from":"paper-bakker-n-engl-j-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration-Positive Patients with Stage IV Squamous Cell Lung C...","note":"Edelman MJ, Redman MW, Albain KS, et al. Journal of Thoracic Oncology.","from":"paper-lung-map-j-thorac-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Systematic review of management of incidental gallbladder cancer after cholecystectomy","note":"Søreide K, Guest RV, Harrison EM, et al. British Journal of Surgery.","from":"paper-soreide-incidental-gallbladder-cancer-review-bjs-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Systematic review of photobiomodulation for the management of oral mucositis in cancer patients and clinical practice guidelines","note":"Zadik Y, Arany PR, Fregnani ER, et al. Supportive care in cancer.","from":"paper-zadik-support-care-cancer","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm","note":"Pemmaraju N, Lane AA, Sweet KL, et al. New England Journal of Medicine.","from":"paper-pemmaraju-n-engl-j-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma","note":"Damato BE, Dukes J, Goodall H, et al. Cancers.","from":"paper-tebentafusp-melanoma-cancers-basel-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Telomeres and telomerase: three decades of progress","note":"Shay JW, Wright WE. Nature reviews. Genetics.","from":"paper-shay-nat-rev-genet","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia","note":"Crockett SD, Nagtegaal ID. Gastroenterology.","from":"paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"The landscape of somatic mutation in normal colorectal epithelial cells","note":"Lee-Six H, Olafsson S, Ellis P, et al. Nature.","from":"paper-lee-six-somatic-mutation-normal-colorectal-crypts-nature-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"The molecular origin and taxonomy of mucinous ovarian carcinoma","note":"Cheasley D, Wakefield MJ, Ryland GL, et al. Nature Communications.","from":"paper-cheasley-mucinous-ovarian-genomics-nat-commun-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical...","note":"Murphy JE, Wo JY, Ryan DP, et al. JAMA Oncology.","from":"paper-murphy-jama-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Treatment of a first patient with FLASH-radiotherapy","note":"Bourhis J, Sozzi WJ, Jorge PG, et al. Radiotherapy and Oncology.","from":"paper-bourhis-radiother-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Trends in the US and Canadian Pathologist Workforces From 2007 to 2017","note":"Metter DM, Colgan TJ, Leung ST, et al. JAMA network open.","from":"paper-metter-jama-netw-open","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-contr...","note":"Jiang Z, Li W, Hu X, et al. The Lancet Oncology.","from":"paper-jiang-lancet-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Tumor-infiltrating lymphocytes and prognosis: a pooled individual patient analysis of early-stage triple-negative breast cancers","note":"Loi S, Drubay D, Adams S, et al. Journal of Clinical Oncology.","from":"paper-loi-tils-pooled-early-tnbc-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion","note":"O'Reilly EM, Hechtman JF. Annals of Oncology.","from":"paper-oreilly-hechtman-ntrk-fusion-pancreatic-larotrectinib-ann-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase...","note":"Widmark A, Gunnlaugsson A, Beckman L, et al. The Lancet.","from":"paper-widmark-lancet","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Unger: most patients never get the chance to join a cancer trial, and when offered, half say yes","note":"Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. JNCI: Journal of the National Cancer Institute.","from":"paper-unger-trial-participation-barriers-jnci-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 thro...","note":"Scott LC, Mobley LR, Kuo TM, et al. Cancer.","from":"paper-scott-tnbc-disparities-uscs-cancer-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Use of Endocrine Therapy for Breast Cancer Risk Reduction: ASCO Clinical Practice Guideline Update","note":"Visvanathan K, Fabian CJ, Bantug E, et al. Journal of Clinical Oncology.","from":"paper-andrea-decensi-j-clin-oncol-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study","note":"Rothwell DG, Ayub M, Cook N, et al. Nature Medicine.","from":"paper-rothwell-nat-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study","note":"Donadieu J, Larabi IA, Tardieu M, et al. Journal of Clinical Oncology.","from":"paper-donadieu-vemurafenib-refractory-multisystem-lch-jco-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-lab...","note":"Bisogno G, De Salvo GL, Bergeron C, et al. The Lancet Oncology.","from":"paper-bisogno-lancet-oncol","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"VISTA is an acidic pH-selective ligand for PSGL-1","note":"Johnston RJ, Su LJ, Pinckney J, et al. Nature.","from":"paper-johnston-nature","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease","note":"Manson JE, Cook NR, Lee IM, et al. New England Journal of Medicine.","from":"paper-manson-n-engl-j-med","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study","note":"Staaf J, Glodzik D, Bosch A, et al. Nature Medicine.","from":"paper-staaf-tnbc-whole-genome-scan-b-nat-med-2019","refs":[]},{"group":"paper","date":"2019","precision":"year","title":"WRN helicase is a synthetic lethal target in microsatellite unstable cancers","note":"Chan EM, Shibue T, McFarland JM, et al. Nature.","from":"paper-chan-nature","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, com...","note":"Lancet Oncology","from":"jeremie-calais","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial","note":"Lancet","from":"xavier-pivot","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE)","note":"Lancet","from":"helena-earl","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"68Ga-FAPI PET/CT: biodistribution and preliminary dosimetry estimate of 2 DOTA-containing FAP-targeting agents","note":"Journal of Nuclear Medicine","from":"frederik-giesel","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer","note":"Journal of Nuclear Medicine","from":"uwe-haberkorn","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors","note":"Clinical Cancer Research","from":"yamamoto-noboru","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer (Ge...","note":"Annals of Oncology","from":"sibylle-loibl","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"A selective small-molecule STAT3 degrader achieves complete tumor regression in vivo","note":"Cancer Cell","from":"shaomeng-wang","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Advances in cancer immunotherapy 2019 – latest trends","note":"Journal of Experimental & Clinical Cancer Research","from":"michael-von-bergwelt","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"ALDH1A1‐related stemness in high‐grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR‐PI3K/aurora kinase inhib...","note":"The Journal of Pathology","from":"annika-auranen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","note":"NEJM","from":"fabrice-andre","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"An upfront immunomodulatory therapy protocol for pediatric opsoclonus‐myoclonus syndrome","note":"Pediatric Blood & Cancer","from":"meredith-irwin","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma","note":"NEJM","from":"noopur-raje","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer","note":"Annals of Oncology","from":"eric-small","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Apalutamide for metastatic, castration-sensitive prostate cancer (TITAN)","note":"NEJM","from":"kim-chi","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","note":"JAMA Oncology","from":"thomas-hope","refs":["johannes-czernin"]},{"group":"person-paper","date":"2019","precision":"year","title":"Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non–Small Cell Lung Cancer With Use of a Next-Generation...","note":"JAMA Oncology","from":"wang-jie-cams","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G4 Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal...","note":"Journal of Clinical Oncology","from":"guo-jun","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors","note":"European Journal of Nuclear Medicine and Molecular Imaging","from":"peter-bartenstein","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices","note":"ASCO Educational Book","from":"nathan-pennell","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myelom...","note":"Lancet","from":"philippe-moreau","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"c-Jun overexpression in CAR T cells induces exhaustion resistance","note":"Nature","from":"crystal-mackall","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Capecitabine compared with observation in resected biliary tract cancer (BILCAP)","note":"Lancet Oncology","from":"john-bridgewater","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy","note":"Nature","from":"weiping-zou","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Cell-free circulating tumor DNA in patients with high-grade glioma as diagnostic biomarker – A guide to future directive","note":"Indian Journal of Cancer","from":"t-naveen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma","note":"Journal of Experimental & Clinical Cancer Research","from":"yu-jinming","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Characterization of Intraductal Papillary Neoplasm of the Bile Duct with Respect to the Histopathologic Similarities to Pancreatic Intraductal Papillary Mucinou...","note":"Gut and Liver","from":"katsuhiko-uesaka","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Chemokine modulation to enhance T cell infiltration of tumors","note":"Cancer Immunology Research","from":"pawel-kalinski","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","note":"NEJM","from":"joseph-sparano","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer","note":"Clinical Cancer Research","from":"natasha-leighl","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Clinical-grade computational pathology using weakly supervised deep learning on whole slide images","note":"Nature Medicine","from":"thomas-fuchs","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Colonization with multidrug resistant organisms determines the clinical course of patients with acute myeloid leukemia undergoing intensive induction chemothera...","note":"PLOS ONE","from":"christian-brandts","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","note":"Annals of Oncology","from":"ulrich-keilholz","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma (MAIA)","note":"NEJM","from":"thierry-facon","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer","note":"Nature Medicine","from":"jakob-nikolas-kather","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group...","note":"European Journal of Cancer","from":"gilles-vassal","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation","note":"Nature Biotechnology","from":"robert-langer","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Delivery technologies for cancer immunotherapy","note":"Nature Reviews Drug Discovery","from":"robert-langer","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Determining the value contribution of emicizumab (Hemlibra ® ) for the prophylaxis of haemophilia A with inhibitors in Spain by multi-criteria decision analysis","note":"Global & Regional Health Technology Assessment","from":"rafael-perez-santamarina","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer","note":"Annals of Oncology","from":"ziyu-li","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Diagnostic ability of artificial intelligence using deep learning analysis of cyst fluid in differentiating malignant from benign pancreatic cystic lesions","note":"Scientific Reports","from":"yasumasa-niwa","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled tri...","note":"The Lancet Gastroenterology & Hepatology","from":"fukuda-haruhiko","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups","note":"Nature","from":"carlos-caldas","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma","note":"Lancet Oncology","from":"steven-clifford","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","note":"Annals of Oncology","from":"ohno-shinji","refs":["frederique-penault-llorca"]},{"group":"person-paper","date":"2019","precision":"year","title":"Early Detection of Pancreatic Cancer: Opportunities and Challenges","note":"Gastroenterology","from":"anirban-maitra","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long-term Survival Among Patients With Stage I Gastric Cancer: The KLASS-01 Randomized C...","note":"JAMA Oncology","from":"han-kwang-yang","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Tri...","note":"JAMA","from":"julie-park","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Effects of Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized interventio...","note":"BMJ","from":"ziyu-li","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Embedding a positive research culture that fosters innovation","note":"Nature Reviews Cancer","from":"iain-foulkes","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Emerging multimodality approaches to treat localized esophageal cancer","note":"Journal of the National Comprehensive Cancer Network","from":"ronan-kelly","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer (BEACON)","note":"NEJM","from":"josep-tabernero","refs":["scott-kopetz"]},{"group":"person-paper","date":"2019","precision":"year","title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer (ENZAMET)","note":"NEJM","from":"christopher-sweeney","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Epidemiological Characteristics of Advanced Hepatocellular Carcinoma in the Northern Region of Vietnam","note":"Cancer Control","from":"le-van-quang","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis","note":"Cancer Cell","from":"owen-sansom","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Epithelial ovarian cancer","note":"The Lancet","from":"charlie-gourley","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent d...","note":"Annals of Oncology","from":"nicoletta-colombo","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update","note":"European Urology","from":"shahrokh-f-shariat","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone","note":"Journal of Clinical Oncology","from":"rana-mckay","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types","note":"JAMA Oncology","from":"wang-feng-sysucc","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Expanding the Boundaries of RNA Sequencing as a Diagnostic Tool for Rare Mendelian Disease","note":"American Journal of Human Genetics","from":"ronald-cohn","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Feasibility and Safety of Endoscopic Thyroidectomy Via a Unilateral Axillobreast Approach for Unilateral Benign Thyroid Tumor in Vietnam","note":"Surgical Laparoscopy, Endoscopy & Percutaneous Techniques","from":"le-van-quang","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"First-in-human trial of rhIL-15 and haploidentical natural killer cell therapy for advanced acute myeloid leukemia","note":"Blood Advances","from":"jeffrey-miller","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma (CheckMate 067)","note":"NEJM","from":"james-larkin","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"General population normative data for the EORTC QLQ-C30 health-related quality of life questionnaire based on 15,386 persons across 13 European countries, Canad...","note":"European Journal of Cancer","from":"sandra-nolte","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma","note":"Nature Genetics","from":"zeng-mu-sheng","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma","note":"Blood","from":"jackson-orem","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients","note":"Blood","from":"lars-bullinger","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML (ADMIRAL)","note":"NEJM","from":"alexander-perl","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Global vascular guidelines on the management of chronic limb-threatening ischemia","note":"Journal of Vascular Surgery","from":"frank-vermassen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of th...","note":"Gynecologic Oncology","from":"richard-barakat","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour W...","note":"Journal of Clinical Oncology","from":"uta-dirksen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Human cord blood (hCB)-CD34+ humanized mice fail to reject human acute myeloid leukemia cells","note":"PLOS ONE","from":"pier-giuseppe-pelicci","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study","note":"JCO","from":"peter-hillmen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","note":"Annals of Oncology","from":"gerard-zalcman","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Impact of Initiating Screening Programs on Referral and Management of Cervical Cancer in Tanzania","note":"Journal of Global Oncology","from":"diwani-msemo","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Implementing lung cancer screening: baseline results from a community-based Lung Health Check pilot in deprived areas of Manchester","note":"Thorax","from":"philip-crosbie","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Inflammatory cytokines and change of Th1/Th2 balance as prognostic indicators for hepatocellular carcinoma in patients treated with transarterial chemoembolizat...","note":"Scientific Reports","from":"yoon-seung-kew","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer","note":"OncoImmunology","from":"eliane-piaggio","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Integrated proteogenomic characterization of HBV-related hepatocellular carcinoma","note":"Cell","from":"fan-jia","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 tria...","note":"Lancet Oncology","from":"graham-jackson","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Liquid biopsy and minimal residual disease: latest advances and implications for cure","note":"Nature Reviews Clinical Oncology","from":"klaus-pantel","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Long-term quality of life in patients treated with extracorporeal membrane oxygenation for postcardiotomy cardiogenic shock","note":"Perfusion","from":"tomas-jovaisa","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers","note":"Nature Biomedical Engineering","from":"tan-weihong","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer (POLO)","note":"NEJM","from":"talia-golan","refs":["hedy-kindler"]},{"group":"person-paper","date":"2019","precision":"year","title":"Making sense of adjuvant chemotherapy in colorectal cancer","note":"Journal of Gastrointestinal Oncology","from":"chee-cheng-ean","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Malignant triton tumor diagnosed twelve years after radiosurgically treated vestibular schwannoma","note":"Clinical Neurology and Neurosurgery","from":"florian-roser","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","note":"Blood","from":"lars-bullinger","refs":["thomas-kindler"]},{"group":"person-paper","date":"2019","precision":"year","title":"Mitochondrial dynamics and metastasis","note":"Cellular and Molecular Life Sciences","from":"dario-altieri","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Molecular landmarks of tumor hypoxia across cancer types","note":"Nat Genet","from":"rob-bristow","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Molecular subtyping and genomic profiling expose precision therapy strategies in triple-negative breast cancer","note":"Cancer Cell","from":"shao-zhi-ming","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations","note":"Gastroenterology","from":"jurgen-weitz","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive V...","note":"Journal of Clinical Oncology","from":"d-wade-clapp","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Negative Predictive Biomarkers in Colorectal Cancer: PRESSING Ahead","note":"Journal of Clinical Oncology","from":"chee-cheng-ean","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma","note":"Nature Medicine","from":"timothy-cloughesy","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Neoadjuvant Vismodegib and Mohs Micrographic Surgery for Locally Advanced Periocular Basal Cell Carcinoma","note":"Ophthalmic Plastic & Reconstructive Surgery","from":"roxana-del-aguila","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer","note":"New England Journal of Medicine","from":"antonio-gonzalez-martin","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3)","note":"Lancet Oncology","from":"ken-kato","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Non-obstetric complications in preeclampsia","note":"Prz Menopauzalny","from":"tomasz-maciejewski","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer (PAOLA-1)","note":"NEJM","from":"isabelle-ray-coquard","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Online adaptive magnetic resonance guided radiotherapy for pancreatic cancer: state of the art, pearls and pitfalls","note":"Radiation Oncology","from":"vincenzo-valentini","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation...","note":"The Lancet Haematology","from":"jurgen-kuball","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer","note":"New England Journal of Medicine","from":"debu-tripathy","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Overall survival with ribociclib plus endocrine therapy in breast cancer (MONALEESA-7)","note":"NEJM","from":"im-seock-ah","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value","note":"Cell Reports","from":"pier-giuseppe-pelicci","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Paget’s disease of the nipple in a Her2-positive breast cancer xenograft model","note":"Breast Cancer Research and Treatment","from":"dorraya-el-ashry","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal HR+ metastatic breast cancer (Young-PEARL)","note":"Lancet Oncology","from":"park-yeon-hee","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pancreatic cancer disparities in African Americans","note":"Pancreas","from":"selwyn-vickers","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-04...","note":"Lancet","from":"barbara-burtness","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma (KEYNOTE-426)","note":"NEJM","from":"brian-rini","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b–2 trial","note":"The Lancet Oncology","from":"thomas-bachelot","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040)","note":"Lancet","from":"ezra-cohen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes","note":"European Urology","from":"markus-graefen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN)","note":"Lancet","from":"william-tap","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppres...","note":"Annals of Oncology","from":"mario-campone","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Phase III trial of PROSTVAC in asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer","note":"Journal of Clinical Oncology","from":"james-gulley","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial","note":"Breast Cancer Res","from":"robert-separovic","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy (EV-201)","note":"JCO","from":"jonathan-rosenberg","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast c...","note":"Annals of Oncology","from":"andrew-wardley","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Professional Oral Care Reduces Carcinogenic Acetaldehyde Levels in Mouth Air of Perioperative Esophageal Cancer Patients: A Prospective Comparative Study","note":"The Tohoku Journal of Experimental Medicine","from":"takashi-kamei","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Prognostic and Therapeutic Implications of Microvascular Invasion in Hepatocellular Carcinoma","note":"Annals of Surgical Oncology","from":"kenneth-tanabe","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Prognostic and Therapeutic Value of Day 14 Bone Marrow Aspiration in Adult Acute Myeloid Leukemia Patients","note":"Clinical Lymphoma Myeloma and Leukemia","from":"mohamed-abdel-moaty-samra","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CON...","note":"Annals of Oncology","from":"fiona-blackhall","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the P...","note":"JCO","from":"andrew-armstrong","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202)","note":"Journal of Clinical Oncology (ASCO Annual Meeting abstract)","from":"emily-bergsland","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and Target","note":"Cancers","from":"giampaolo-tortora","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Putting patients first: an inventive service delivering cancer treatment at home","note":"Journal of Comparative Effectiveness Research","from":"joan-spencer","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized...","note":"Journal of Clinical Oncology","from":"ma-fei","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Quality of Life in Patients With Low-Risk Prostate Cancer Treated With Hypofractionated vs Conventional Radiotherapy: A Phase 3 Randomized Clinical Trial","note":"JAMA Oncology","from":"deborah-bruner","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Quantitative evidence for early metastatic seeding in colorectal cancer","note":"Nature Genetics","from":"christina-curtis","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Radiomics: Principles and radiotherapy applications","note":"Critical Reviews in Oncology/Hematology","from":"pierre-vera","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016)","note":"Lancet","from":"maura-gillison","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV)","note":"Lancet","from":"hisham-mehanna","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unkno...","note":"Journal of Clinical Oncology","from":"hidetoshi-hayashi","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Real-World Experience of Palbociclib-Induced Adverse Events and Compliance With Complete Blood Count Monitoring in Women With Hormone Receptor–Positive/HER2-Neg...","note":"Clinical Breast Cancer","from":"john-kennedy","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study","note":"Lancet Oncology","from":"tanios-bekaii-saab","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Revising the WHO classification: female genital tract tumours","note":"Histopathology","from":"cree-ian","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Role of Baseline Albumin-Bilirubin Grade on Predict Overall Survival Among Sorafenib-Treated Patients With Hepatocellular Carcinoma in Vietnam","note":"Cancer Control","from":"le-van-quang","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Safety and efficacy of durvalumab with or without tremelimumab in patients with PD-L1-low/negative recurrent or metastatic HNSCC (CONDOR)","note":"JAMA Oncology","from":"lillian-siu","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 anti...","note":"Annals of Oncology","from":"wang-feng-sysucc","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Second round results from the Manchester Lung Health Check community-based targeted lung cancer screening pilot","note":"Thorax","from":"philip-crosbie","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Secondary surgical cytoreduction for recurrent ovarian cancer (GOG-0213)","note":"NEJM","from":"robert-coleman","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Sentinel lymph node mapping using indocyanine green in patients with uterine and cervical neoplasms: restrictions of the method","note":"Arch Gynecol Obstet","from":"tomasz-maciejewski","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET)","note":"Lancet","from":"david-palma","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality","note":"JAMA Oncology","from":"markus-graefen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation","note":"JNCI","from":"joseph-unger","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination","note":"Nature Medicine","from":"joshua-brody","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant","note":"Nature Medicine","from":"philip-greenberg","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Targeting mutant p53 in cancer: the latest insights","note":"Journal of Experimental & Clinical Cancer Research","from":"giovanni-blandino","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Targeting MYCN and ALK in resistant and relapsing neuroblastoma","note":"Cancer Drug Resistance","from":"louis-chesler","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"The advantage of FLASH radiotherapy confirmed in mini-pig and cat-cancer patients","note":"Clinical Cancer Research","from":"marie-catherine-vozenin","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs","note":"Nature","from":"emile-voest","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"The European Prostate Cancer Centres of Excellence: A Novel Proposal from the European Association of Urology Prostate Cancer Centre Consensus Meeting","note":"European Urology","from":"barbara-jereczek-fossa","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"The Influence of the Perioperative Nutritional Status on the Survival Outcomes for Esophageal Cancer Patients with Neoadjuvant Chemotherapy","note":"Annals of Surgical Oncology","from":"takashi-kamei","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy","note":"International Journal of Gynecological Cancer","from":"anna-fagotti","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","note":"Journal for ImmunoTherapy of Cancer","from":"ezra-cohen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"TheraP: a randomized phase 2 trial of 177 Lu‐ PSMA ‐617 theranostic treatment vs cabazitaxel in progressive metastatic castration‐resistant prostate cancer (Cli...","note":"BJU International","from":"ian-davis","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Time from Symptom Onset to Diagnosis and Treatment among Haematological Malignancies: Influencing Factors and Associated Negative Outcomes","note":"Medicina","from":"valdas-peceliunas","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma (JULIET)","note":"NEJM","from":"stephen-schuster","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1–2 trial","note":"The Lancet Oncology","from":"dearbhaile-collins","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study","note":"Lancet Oncology","from":"doi-toshihiko","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","note":"New England Journal of Medicine","from":"charles-geyer","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer (KATHERINE)","note":"NEJM","from":"gunter-von-minckwitz","refs":["eleftherios-mamounas"]},{"group":"person-paper","date":"2019","precision":"year","title":"Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study","note":"Leukemia","from":"yuqin-song","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Tumor genomic profiling guides patients with metastatic gastric cancer to targeted treatment: the VIKTORY umbrella trial","note":"Cancer Discovery","from":"lee-jeeyun","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Tumor microenvironment and breast cancer survival: combined effects of breast fat, M2 macrophages and hyaluronan create a dismal prognosis","note":"Breast Cancer Research and Treatment","from":"satu-tiainen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spa...","note":"Clinical and Translational Oncology","from":"pilar-garrido","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42)","note":"Lancet Oncology","from":"eleftherios-mamounas","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Usefulness of Deep Learning Analysis for the Diagnosis of Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas","note":"Clinical and Translational Gastroenterology","from":"yasumasa-niwa","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Vaccine Strategies to Improve Anti-cancer Cellular Immune Responses","note":"Frontiers in Immunology","from":"karim-vermaelen","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Variability in breast cancer surgery training across Europe: An ESSO-EUSOMA international survey","note":"European Journal of Surgical Oncology","from":"isabel-rubio","refs":[]},{"group":"person-paper","date":"2019","precision":"year","title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions (CLL14)","note":"NEJM","from":"michael-hallek","refs":["kirsten-fischer"]},{"group":"technology","date":"2019","precision":"year","title":"HRD genomic scar scores (GIS, LOH, HRDetect)","note":"First use in humans or first approval, as the technology record states it.","from":"hrd-genomic-scar-scores","refs":[]},{"group":"technology","date":"2019","precision":"year","title":"NHS Targeted Lung Health Check (lung cancer screening programme)","note":"First use in humans or first approval, as the technology record states it.","from":"nhs-targeted-lung-health-check","refs":[]},{"group":"technology","date":"2019","precision":"year","title":"Stereotactic ablative radiotherapy for oligometastatic disease","note":"First use in humans or first approval, as the technology record states it.","from":"sabr-oligometastases","refs":[]},{"group":"trial","date":"2019","precision":"year","title":"A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) reported","from":"nct02441309","refs":["osteosarcoma","mifamurtide","ifosfamide"]},{"group":"trial","date":"2019","precision":"year","title":"A Phase 2 Study of BGJ398 in Patients With Recurrent GBM reported","from":"nct01975701","refs":["glioblastoma","infigratinib"]},{"group":"trial","date":"2019","precision":"year","title":"A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer reported","from":"nct02747004","refs":["metastatic-cancer","abemaciclib","tamoxifen"]},{"group":"trial","date":"2019","precision":"year","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC reported","note":"Radiographic progression-free survival at 24 months 68.2 percent with apalutamide added to androgen deprivation against 47.5 percent with placebo (hazard ratio 0.48, 95 percent con...","from":"nct02489318","refs":["prostate","prostate-mhspc","apalutamide"]},{"group":"trial","date":"2019","precision":"year","title":"ABC-06 reported","note":"Modified FOLFOX plus active symptom control modestly improved overall survival over active symptom control alone.","from":"abc-06","refs":["cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma","gallbladder"]},{"group":"trial","date":"2019","precision":"year","title":"ACNS0121 reported","note":"Five-year event-free survival 68.5 percent with immediate post-operative conformal radiotherapy, 61.4 percent with observation after complete resection of differentiated supratento...","from":"acns0121","refs":["ependymoma","brain-tumours","childhood-cancers","carboplatin"]},{"group":"trial","date":"2019","precision":"year","title":"ACNS1123 reported","note":"Three-year progression-free survival 87.8 percent and overall survival 92.4 percent for non-germinomatous tumours given reduced whole-ventricular radiotherapy after a response to c...","from":"acns1123","refs":["cns-germ-cell-tumours","paediatric-germ-cell-tumours","brain-tumours","childhood-cancers"]},{"group":"trial","date":"2019","precision":"year","title":"Act.In.Sarc reported","note":"Pathological complete response 16% (14 of 87) with NBTXR3 plus radiotherapy versus 8% (7 of 89) with radiotherapy alone (p=0.044).","from":"act-in-sarc","refs":["sarcoma","nbtxr3"]},{"group":"trial","date":"2019","precision":"year","title":"ADMIRAL reported","note":"OS 9.3 vs 5.6 months; HR 0.64.","from":"admiral","refs":["aml","aml-flt3","gilteritinib"]},{"group":"trial","date":"2019","precision":"year","title":"ALESIA reported","note":"Investigator-assessed progression-free survival significantly longer with alectinib than crizotinib, consistent with the global ALEX trial.","from":"alesia","refs":["alk-positive-nsclc","alectinib","crizotinib"]},{"group":"trial","date":"2019","precision":"year","title":"ANBL0531 reported","note":"Three-year event-free survival 83.2 percent and overall survival 94.9 percent with response- and biology-based reduction of chemotherapy; overall survival 100 percent for localised...","from":"anbl0531","refs":["neuroblastoma-intermediate-risk","neuroblastoma","childhood-cancers","carboplatin"]},{"group":"trial","date":"2019","precision":"year","title":"ANNOUNCE reported","note":"OS HR 1.05 (negative); drug withdrawn.","from":"announce","refs":["sarcoma","extremity-soft-tissue-sarcoma","doxorubicin","olaratumab"]},{"group":"trial","date":"2019","precision":"year","title":"ARAMIS reported","note":"Darolutamide lengthened metastasis-free and overall survival compared with placebo with a near-placebo side-effect profile; approved in July 2019.","from":"aramis","refs":["prostate-nmcrpc","prostate","darolutamide"]},{"group":"trial","date":"2019","precision":"year","title":"ARCHES reported","note":"rPFS HR 0.39; OS HR 0.66.","from":"arches","refs":["prostate","prostate-mhspc","enzalutamide"]},{"group":"trial","date":"2019","precision":"year","title":"ARMOR3-SV reported","note":"Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men.","from":"armor3-sv","refs":["prostate","prostate-mcrpc","galeterone","enzalutamide"]},{"group":"trial","date":"2019","precision":"year","title":"ASTRA reported","note":"Complete remission 40% vs 38.5%; not significant.","from":"astra","refs":["thyroid"]},{"group":"trial","date":"2019","precision":"year","title":"AUGMENT reported","note":"Lenalidomide plus rituximab substantially lengthened progression-free survival compared with rituximab alone; approved in May 2019.","from":"augment","refs":["follicular-lymphoma","marginal-zone-lymphoma","non-hodgkin-lymphoma","lenalidomide"]},{"group":"trial","date":"2019","precision":"year","title":"BEACON CRC reported","note":"Median overall survival 9.3 months (encorafenib-cetuximab, with or without binimetinib) vs 5.9 months (chemotherapy plus cetuximab); response rate 20% (doublet) vs 2%.","from":"beacon-crc","refs":["colorectal","braf-v600e-colorectal","encorafenib","binimetinib"]},{"group":"trial","date":"2019","precision":"year","title":"CAO/ARO/AIO-12 reported","note":"Pathological complete response 25 percent with consolidation chemotherapy against 17 percent with induction.","from":"cao-aro-aio-12","refs":["colorectal","rectal-cancer","folfox","fluorouracil"]},{"group":"trial","date":"2019","precision":"year","title":"CARD reported","note":"Median imaging-based progression-free survival 8.0 against 3.7 months (hazard ratio 0.54, 95 percent confidence interval 0.40 to 0.73) and overall survival 13.6 against 11.0 months...","from":"card","refs":["prostate","prostate-mcrpc","cabazitaxel","abiraterone"]},{"group":"trial","date":"2019","precision":"year","title":"CASPIAN reported","note":"OS 13.0 vs 10.3 months, HR 0.73; 3-year OS 17.6% vs 5.8%.","from":"caspian","refs":["sclc","extensive-stage-sclc","durvalumab","tremelimumab"]},{"group":"trial","date":"2019","precision":"year","title":"CASSIOPEIA reported","note":"Daratumumab added to VTd increased stringent complete responses and lengthened progression-free survival; approved for transplant-eligible myeloma in 2019 (EU) and 2020 (US).","from":"cassiopeia","refs":["myeloma-transplant-eligible","multiple-myeloma","daratumumab","bortezomib"]},{"group":"trial","date":"2019","precision":"year","title":"CheckMate 227 reported","note":"Nivolumab plus ipilimumab improved overall survival over chemotherapy in PD-L1-positive advanced non-small-cell lung cancer; approved in the United States in May 2020.","from":"checkmate-227","refs":["pdl1-high-nsclc","nsclc","lung-cancer","nivolumab"]},{"group":"trial","date":"2019","precision":"year","title":"CHISEL (TROG 09.02) reported","note":"Local failure hazard ratio 0.32 favouring SABR; median overall survival 5 years vs 3 years.","from":"chisel","refs":["nsclc","resectable-nsclc"]},{"group":"trial","date":"2019","precision":"year","title":"CLL14 reported","note":"6-year PFS 53.1% vs 21.7%; HR 0.40.","from":"cll14","refs":["cll","cll-treatment-naive","venetoclax","obinutuzumab"]},{"group":"trial","date":"2019","precision":"year","title":"COLOPEC reported","note":"Peritoneal metastasis-free survival at 18 months 80.9 against 76.2 percent: no benefit.","from":"colopec","refs":["colorectal","colon-cancer","oxaliplatin","capox"]},{"group":"trial","date":"2019","precision":"year","title":"Combination of External Beam Radiotherapy With 153Sm-EDTMP to Treat High Risk Osteosarcoma reported","from":"nct01886105","refs":["osteosarcoma","samarium-153-lexidronam"]},{"group":"trial","date":"2019","precision":"year","title":"De-ESCALaTE HPV reported","note":"Severe toxicity similar; 2-year overall survival 97.5% (cisplatin) vs 89.4% (cetuximab).","from":"de-escalate","refs":["head-and-neck","oropharyngeal-cancer","hpv-positive-oropharyngeal-cancer","cisplatin"]},{"group":"trial","date":"2019","precision":"year","title":"ECLIPSE (GVAX pancreas and CRS-207) reported","note":"Median overall survival 3.7 months with cyclophosphamide, GVAX pancreas and CRS-207 against 4.6 months with chemotherapy in the primary cohort (hazard ratio 1.17, 95 percent confid...","from":"eclipse","refs":["pancreatic","metastatic-pdac","cyclophosphamide"]},{"group":"trial","date":"2019","precision":"year","title":"Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Explorator...","from":"nct01876043","refs":["liposarcoma","plitidepsin"]},{"group":"trial","date":"2019","precision":"year","title":"ELEVATE-TN reported","note":"6-year median PFS not reached vs 27.8 months; OS HR 0.62 (A+O).","from":"elevate-tn","refs":["cll","cll-treatment-naive","acalabrutinib","obinutuzumab"]},{"group":"trial","date":"2019","precision":"year","title":"ENLIVEN reported","note":"Week 25 RECIST response 39% vs 0% (placebo); FDA approval 2019 with a liver-toxicity REMS.","from":"enliven","refs":["tenosynovial-giant-cell-tumour","sarcoma","pexidartinib"]},{"group":"trial","date":"2019","precision":"year","title":"ENZAMET reported","note":"Enzalutamide added to testosterone suppression improved overall survival compared with a standard non-steroidal antiandrogen.","from":"enzamet","refs":["prostate-mhspc","prostate","enzalutamide","docetaxel"]},{"group":"trial","date":"2019","precision":"year","title":"ERA 223 reported","note":"Median symptomatic skeletal event-free survival 22.3 against 26.0 months (hazard ratio 1.122, 95 percent confidence interval 0.917 to 1.374, p=0.2636): no benefit.","from":"era-223","refs":["prostate","prostate-mcrpc","radium-223","abiraterone"]},{"group":"trial","date":"2019","precision":"year","title":"ERSPC (European Randomized Study of Screening for Prostate Cancer) reported","note":"Rate ratio for prostate cancer death 0.80 (95 percent confidence interval 0.65 to 0.98, adjusted p=0.04) at a median of nine years, and 0.80 (0.72 to 0.89, p<0.001) at 16 years; 1...","from":"erspc","refs":["prostate","prostate-low-risk","prostate-intermediate-risk","prostate-high-risk"]},{"group":"trial","date":"2019","precision":"year","title":"Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer reported","from":"nct02260817","refs":["prostate","choline-c11"]},{"group":"trial","date":"2019","precision":"year","title":"FLOT4-AIO reported","note":"Perioperative FLOT improved overall survival over ECF or ECX in resectable gastric and junctional adenocarcinoma.","from":"flot4","refs":["oesophageal-adenocarcinoma","esophageal","gastric","fluorouracil"]},{"group":"trial","date":"2019","precision":"year","title":"Gemcitabine, cisplatin and nab-paclitaxel phase 2 (MD Anderson and Mayo) reported","note":"Median PFS 11.8 months; partial response 45%; median OS 19.2 months (single arm).","from":"gap-phase2-mdacc","refs":["gallbladder","cholangiocarcinoma","gemcitabine-cisplatin","nab-paclitaxel"]},{"group":"trial","date":"2019","precision":"year","title":"GETUG-AFU 16 reported","note":"Progression-free survival at 120 months 64 percent with salvage radiotherapy plus 6 months of goserelin against 49 percent with radiotherapy alone (hazard ratio 0.54, 95 percent co...","from":"getug-afu-16","refs":["prostate","prostate-bcr","goserelin"]},{"group":"trial","date":"2019","precision":"year","title":"HER2CLIMB reported","note":"OS 21.9 vs 17.4 months, HR 0.66; CNS-PFS HR 0.32.","from":"her2climb","refs":["breast-her2-positive","secondary-brain-tumours","her2-positive-breast-brain-metastases","tucatinib"]},{"group":"trial","date":"2019","precision":"year","title":"HORRAD reported","note":"Median overall survival 45 vs 43 months (hazard ratio 0.90, not significant).","from":"horrad","refs":["prostate","metastatic-cancer"]},{"group":"trial","date":"2019","precision":"year","title":"HYPO-RT-PC reported","note":"5-year failure-free survival 84% in both arms, non-inferior.","from":"hypo-rt-pc","refs":["prostate","prostate-intermediate-risk","prostate-high-risk"]},{"group":"trial","date":"2019","precision":"year","title":"I-PREDICT reported","note":"Individualised combinations were feasible; a matching score above 50 percent was associated with better disease control and longer progression-free and overall survival.","from":"i-predict","refs":["rare-cancers"]},{"group":"trial","date":"2019","precision":"year","title":"iBRA (implant Breast Reconstruction evAluation) reported","note":"Within three months of immediate implant-based reconstruction: implant loss 9 percent, infection needing treatment 25 percent, return to theatre 18 percent and readmission 18 perce...","from":"ibra-study","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2019","precision":"year","title":"IMblaze370 reported","note":"Median overall survival 8.87 months with atezolizumab and cobimetinib against 8.51 months with regorafenib (hazard ratio 1.00).","from":"imblaze370","refs":["colorectal","atezolizumab","cobimetinib","regorafenib"]},{"group":"trial","date":"2019","precision":"year","title":"INTELLANCE-1 reported","note":"Depatuxizumab mafodotin added to radiotherapy and temozolomide did not improve overall survival in EGFR-amplified glioblastoma; stopped for futility.","from":"intellance-1","refs":["glioblastoma","brain-tumours","depatuxizumab-mafodotin","temozolomide"]},{"group":"trial","date":"2019","precision":"year","title":"Interfant-06 reported","note":"6-year EFS 46.1%; intensification no benefit.","from":"interfant-06","refs":["all-leukemia","all-infant","blinatumomab"]},{"group":"trial","date":"2019","precision":"year","title":"KEYNOTE-042 reported","note":"Median overall survival 20.0 vs 12.2 months (PD-L1 50% or more, hazard ratio 0.69); 16.7 vs 12.1 months (1% or more, hazard ratio 0.81); no difference at 1 to 49%.","from":"keynote-042","refs":["nsclc","pdl1-high-nsclc","pembrolizumab","carboplatin"]},{"group":"trial","date":"2019","precision":"year","title":"KEYNOTE-048 reported","note":"OS 14.9 vs 10.7 months (CPS ≥20, monotherapy); 13.0 vs 10.7 (all, with chemotherapy).","from":"keynote-048","refs":["head-and-neck","oropharyngeal-cancer","laryngeal-cancer","oral-cavity-cancer"]},{"group":"trial","date":"2019","precision":"year","title":"KEYNOTE-170 reported","note":"Objective response rate 45%, complete response 13%, in 53 patients with relapsed or refractory disease; FDA accelerated approval June 2018.","from":"keynote-170","refs":["primary-mediastinal-b-cell-lymphoma","dlbcl","pembrolizumab"]},{"group":"trial","date":"2019","precision":"year","title":"KEYNOTE-426 reported","note":"OS HR 0.84 final (47.2 vs 40.8 months); PFS HR 0.69.","from":"keynote-426","refs":["rcc","clear-cell-rcc","pembrolizumab","axitinib"]},{"group":"trial","date":"2019","precision":"year","title":"KLASS-01 reported","note":"Laparoscopic distal gastrectomy was non-inferior to open surgery for five-year overall survival in stage I gastric cancer, with fewer wound complications.","from":"klass-01","refs":["early-gastric-cancer","gastric"]},{"group":"trial","date":"2019","precision":"year","title":"LUME-Meso reported","note":"PFS HR 1.01, negative.","from":"lume-meso","refs":["mesothelioma","nintedanib","pemetrexed"]},{"group":"trial","date":"2019","precision":"year","title":"Lung-SEARCH reported","note":"No clear stage shift (54.8 against 45.2 percent early stage, one-sided p = 0.24); sputum sensitivity 40.5 percent with a 32.8 percent cumulative false-positive rate, and 55 percent...","from":"lungsearch","refs":["nsclc","lung-cancer"]},{"group":"trial","date":"2019","precision":"year","title":"MAIA reported","note":"Daratumumab, lenalidomide and dexamethasone improved progression-free and later overall survival over lenalidomide and dexamethasone in transplant-ineligible newly diagnosed myelom...","from":"maia","refs":["myeloma-transplant-ineligible","multiple-myeloma","daratumumab","lenalidomide"]},{"group":"trial","date":"2019","precision":"year","title":"NRG Oncology RTOG 0521 reported","note":"Four-year overall survival 93 against 89 percent with adjuvant docetaxel added to androgen suppression and radiotherapy (hazard ratio 0.69, 90 percent confidence interval 0.49 to 0...","from":"rtog-0521","refs":["prostate","prostate-high-risk","docetaxel"]},{"group":"trial","date":"2019","precision":"year","title":"NSABP B-39/RTOG 0413 reported","note":"10-year ipsilateral breast tumour recurrence 4.6% (partial breast) vs 3.9% (whole breast); equivalence not established.","from":"nsabp-b39","refs":["breast-hr-positive","breast-her2-positive","tnbc","ductal-carcinoma-in-situ"]},{"group":"trial","date":"2019","precision":"year","title":"ORATOR reported","note":"Swallowing quality of life at one year was statistically but not clinically meaningfully better after radiotherapy than after transoral robotic surgery; oncological outcomes were s...","from":"orator","refs":["hpv-positive-oropharyngeal-cancer","oropharyngeal-cancer","cisplatin"]},{"group":"trial","date":"2019","precision":"year","title":"PAOLA-1 / ENGOT-ov25 reported","note":"PFS HR 0.59 overall, 0.33 HRD-positive; 5-year OS 65.5% vs 48.4% in HRD-positive.","from":"paola-1","refs":["ovarian","high-grade-serous-ovarian-cancer","platinum-sensitive-ovarian-cancer","olaparib"]},{"group":"trial","date":"2019","precision":"year","title":"Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) reported","from":"nct03260894","refs":["rcc","pembrolizumab","epacadostat","sunitinib"]},{"group":"trial","date":"2019","precision":"year","title":"Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669...","from":"nct03358472","refs":["head-and-neck","pembrolizumab","epacadostat","cetuximab"]},{"group":"trial","date":"2019","precision":"year","title":"PERSEPHONE reported","note":"4-year DFS 89.4% vs 89.8%, non-inferior.","from":"persephone","refs":["breast-her2-positive","her2-positive-early-breast-cancer","trastuzumab"]},{"group":"trial","date":"2019","precision":"year","title":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) reported","from":"nct02453282","refs":["nsclc","durvalumab","tremelimumab","carboplatin"]},{"group":"trial","date":"2019","precision":"year","title":"Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy reported","from":"nct02872103","refs":["breast-cancer","efbemalenograstim-alfa"]},{"group":"trial","date":"2019","precision":"year","title":"POLO reported","note":"PFS HR 0.53; OS HR 0.83 (not significant).","from":"polo","refs":["pancreatic","brca-palb2-pdac","olaparib"]},{"group":"trial","date":"2019","precision":"year","title":"PRIMA / ENGOT-OV26 reported","note":"PFS HR 0.62 overall, 0.43 HRD-positive; final OS HR 1.01.","from":"prima","refs":["ovarian","high-grade-serous-ovarian-cancer","platinum-sensitive-ovarian-cancer","niraparib"]},{"group":"trial","date":"2019","precision":"year","title":"PROSPECT reported","note":"Median overall survival 34.4 months with PROSTVAC (hazard ratio 1.01), 33.2 months with PROSTVAC and granulocyte-macrophage colony-stimulating factor (1.02) and 34.3 months with pl...","from":"prospect-prostvac","refs":["prostate","prostate-mcrpc","prostvac"]},{"group":"trial","date":"2019","precision":"year","title":"RAPID (accelerated partial-breast irradiation) reported","note":"Eight-year ipsilateral breast tumour recurrence 3.0 percent with twice-daily partial-breast irradiation against 2.8 percent with whole-breast irradiation (non-inferior), with late...","from":"rapid","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2019","precision":"year","title":"REACH-2 reported","note":"Ramucirumab improved overall survival over placebo in alpha-fetoprotein-high hepatocellular carcinoma after sorafenib; approved in May 2019.","from":"reach-2","refs":["hcc-advanced","hcc","ramucirumab"]},{"group":"trial","date":"2019","precision":"year","title":"REGOBONE reported","note":"Regorafenib improved eight-week progression-free survival over placebo in relapsed osteosarcoma, with signals in the Ewing sarcoma and chondrosarcoma cohorts.","from":"regobone","refs":["osteosarcoma","ewing-sarcoma","chondrosarcoma","chordoma"]},{"group":"trial","date":"2019","precision":"year","title":"RTOG 1016 reported","note":"5-year overall survival 84.6% (cisplatin) vs 77.9% (cetuximab); non-inferiority not met.","from":"rtog-1016","refs":["head-and-neck","oropharyngeal-cancer","hpv-positive-oropharyngeal-cancer","cisplatin"]},{"group":"trial","date":"2019","precision":"year","title":"SABR-COMET: stereotactic ablative radiotherapy for oligometastatic cancer reported","note":"5-year OS 42.3% vs 17.7% (long-term update, JCO 2020).","from":"sabr-comet","refs":["metastatic-cancer","breast-hr-positive","nsclc","colorectal"]},{"group":"trial","date":"2019","precision":"year","title":"Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy reported","from":"nct02144077","refs":["basal-cell-carcinoma","aminolevulinic-acid","methyl-aminolevulinate"]},{"group":"trial","date":"2019","precision":"year","title":"STELLAR reported","note":"Median OS 18.2 months (single arm) vs 12.1 historical.","from":"stellar","refs":["mesothelioma","optune","pemetrexed"]},{"group":"trial","date":"2019","precision":"year","title":"Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) reported","from":"nct02362594","refs":["melanoma","stage-iii-melanoma","pembrolizumab"]},{"group":"trial","date":"2019","precision":"year","title":"Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Ce...","from":"nct02674568","refs":["sclc","rovalpituzumab-tesirine"]},{"group":"trial","date":"2019","precision":"year","title":"TAM-01 reported","note":"Tamoxifen 5 mg daily for three years roughly halved breast cancer events compared with placebo with few serious adverse effects.","from":"tam-01","refs":["ductal-carcinoma-in-situ","breast-cancer","tamoxifen"]},{"group":"trial","date":"2019","precision":"year","title":"TAPPAS reported","note":"Adding TRC105 to pazopanib did not improve progression-free survival; stopped for futility.","from":"tappas","refs":["angiosarcoma","vascular-tumours","sarcoma","carotuximab"]},{"group":"trial","date":"2019","precision":"year","title":"WINTHER reported","note":"Primary endpoint (progression-free survival ratio against the prior line) not met in either arm; transcriptomic matching was feasible and higher matching scores tracked with longer...","from":"winther","refs":["rare-cancers"]},{"group":"regulatory","date":"2019-02-28","precision":"day","title":"Trastuzumab: approval (US)","note":"Subcutaneous trastuzumab-hyaluronidase (Herceptin Hylecta)","from":"trastuzumab","refs":[]},{"group":"regulatory","date":"2019-03","precision":"month","title":"Atezolizumab: approval (US)","note":"Accelerated approval with nab-paclitaxel for PD-L1-positive (SP142 IC 1 percent or more) unresectable locally advanced or metastatic TNBC on IMpassion130 progression-free survival","from":"atezolizumab","refs":[]},{"group":"regulatory","date":"2019-03-08","precision":"day","title":"Atezolizumab: approval (US)","note":"PD-L1+ metastatic TNBC with nab-paclitaxel (accelerated; IMpassion130)","from":"atezolizumab","refs":[]},{"group":"regulatory","date":"2019-03-18","precision":"day","title":"Atezolizumab: approval (US)","note":"Extensive-stage SCLC with chemotherapy (IMpower133)","from":"atezolizumab","refs":[]},{"group":"guideline","date":"2019-04","precision":"month","title":"NCCN 2018-2019 updates for Renal cell carcinoma","note":"1 row recategorised. Anchored to FDA approvals of nivolumab plus ipilimumab (April 2018, CheckMate 214) and pembrolizumab plus axitinib (April 2019, KEYNOTE-426).","from":"rcc","refs":["nivolumab","ipilimumab","pembrolizumab","axitinib"]},{"group":"regulatory","date":"2019-04-04","precision":"day","title":"Palbociclib: approval (US)","note":"Men with HR+/HER2- breast cancer","from":"palbociclib","refs":[]},{"group":"guideline","date":"2019-05","precision":"month","title":"NCCN 2019 update for HER2-positive breast cancer","note":"1 row added. Anchored to FDA approval of adjuvant trastuzumab emtansine for residual disease, May 2019 (KATHERINE).","from":"breast-her2-positive","refs":["trastuzumab-emtansine","katherine"]},{"group":"regulatory","date":"2019-05","precision":"month","title":"Signatera: designation (US)","note":"FDA Breakthrough Device designation","from":"signatera","refs":[]},{"group":"regulatory","date":"2019-05-03","precision":"day","title":"Trastuzumab emtansine: approval (US)","note":"Adjuvant treatment of HER2+ early breast cancer with residual disease (KATHERINE)","from":"trastuzumab-emtansine","refs":[]},{"group":"regulatory","date":"2019-05-15","precision":"day","title":"Venetoclax: approval (US)","note":"First-line CLL with obinutuzumab (CLL14)","from":"venetoclax","refs":[]},{"group":"regulatory","date":"2019-05-23","precision":"day","title":"Optune / Optune Pax (TTFields): approval (US)","note":"Humanitarian device exemption, malignant pleural mesothelioma","from":"optune","refs":[]},{"group":"guideline","date":"2019-06","precision":"month","title":"NCCN 2017-2019 updates for Diffuse large B-cell lymphoma","note":"2 rows added. Anchored to FDA approvals of axicabtagene ciloleucel (October 2017) and tisagenlecleucel (May 2018) in the third line, and polatuzumab vedotin with bendamustine-ritux...","from":"dlbcl","refs":["axicabtagene-ciloleucel","tisagenlecleucel","polatuzumab-vedotin","bendamustine"]},{"group":"guideline","date":"2019-06","precision":"month","title":"NCCN 2019 update for Multiple myeloma","note":"1 row added. Anchored to FDA approval of daratumumab with lenalidomide-dexamethasone for transplant-ineligible patients, June 2019 (MAIA).","from":"multiple-myeloma","refs":["daratumumab","lenalidomide"]},{"group":"regulatory","date":"2019-06-10","precision":"day","title":"Polatuzumab vedotin: approval (US)","note":"Accelerated approval with BR in R/R DLBCL","from":"polatuzumab-vedotin","refs":[]},{"group":"regulatory","date":"2019-06-14","precision":"day","title":"Quizartinib: complete response letter (US)","note":"Complete response letter for relapsed/refractory indication (QuANTUM-R)","from":"quizartinib","refs":[]},{"group":"regulatory","date":"2019-09-17","precision":"day","title":"Lenvatinib: approval (US)","note":"Accelerated approval with pembrolizumab in endometrial cancer (KEYNOTE-146)","from":"lenvatinib","refs":[]},{"group":"guideline","date":"2019-11","precision":"month","title":"NCCN 2019 updates for Chronic lymphocytic leukaemia","note":"2 rows added. Anchored to FDA approvals of venetoclax plus obinutuzumab (May 2019, CLL14) and first-line acalabrutinib (November 2019, ELEVATE-TN).","from":"cll","refs":["venetoclax","obinutuzumab","cll14","acalabrutinib"]},{"group":"regulatory","date":"2019-11-21","precision":"day","title":"Acalabrutinib: approval (US)","note":"CLL/SLL","from":"acalabrutinib","refs":[]},{"group":"regulatory","date":"2019-12","precision":"month","title":"Ciltacabtagene autoleucel: designation (US)","note":"Breakthrough Therapy designation","from":"ciltacabtagene-autoleucel","refs":[]},{"group":"regulatory","date":"2019-12-01","precision":"day","title":"Enasidenib: withdrawal (EU)","note":"Marketing application withdrawn after EMA objections on efficacy","from":"enasidenib","refs":[]},{"group":"regulatory","date":"2019-12-18","precision":"day","title":"Enfortumab vedotin: approval (US)","note":"Accelerated approval, advanced urothelial cancer after platinum and PD-1/PD-L1 (EV-201)","from":"enfortumab-vedotin","refs":[]},{"group":"regulatory","date":"2019-12-20","precision":"day","title":"Trastuzumab deruxtecan: approval (US)","note":"Accelerated approval, HER2+ metastatic breast cancer after ≥2 anti-HER2 regimens (DESTINY-Breast01)","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2019-12-27","precision":"day","title":"Olaparib: approval (US)","note":"gBRCA metastatic pancreatic cancer maintenance (POLO)","from":"olaparib","refs":[]}]},"route":"/years/2019/","neighbours":{"year":[{"id":"2018","kind":"year","name":"2018 in oncology","route":"/years/2018/"},{"id":"2020","kind":"year","name":"2020 in oncology","route":"/years/2020/"}]}}